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Structure based computational peptide design methods have gained significant interest in 
recent years with the availability of structural insights of protein-protein interactions obtained 
from the crystal structures.  Most of these approaches design new peptide ligands by connecting 
the crucial amino acid residues from the protein interface and are generally not based on any 
predicted receptor-ligand interaction.  In this work, a peptide design method based on the Knob-
Socket model was used to identify the specific ligand residues packing into the receptor 
interface.  This method enables rational peptide ligand design by predicting amino acid residues 
that will fit best at the binding site of the receptor protein.  Specific peptide ligands for the model 
receptor CD13 that are overexpressed in several cancer types were designed in this study.  From 
the initial library of designed peptides, three potential candidates were selected based on 
simulated energies in the CD13 binding site using the programs Molecular Operating 
Environment (MOE) and AutoDock Vina.  In the CD13 enzymatic activity inhibition assay, the 
three identified peptides exhibited 2.7 to 7.4 times lower IC50 values (GYPAY, 227 µM; 
GFPAY, 463 µM; GYPAVYLF, 170 µM) when compared to the known peptide ligand 
CNGRC(C1-C5) (1260 µM).  The binding affinities of the peptides (GYPAY, Ki = 54.0 µM; 
GFPAY, Ki = 74.3 µM; GYPAVYLF, Ki = 38.8 µM) were 10 to 20 times higher than that of 
CNGRC (C1-C5) (Ki = 773 µM).  The double reciprocal plots from the steady state enzyme 
8 
kinetic assays confirmed the binding of the peptides to the intended active site of CD13.  The cell 
binding and confocal microscopy assays showed that the designed peptides selectively bind to 
the CD13 on cell surface.  The designed peptide-drug conjugates (PDCs) showed lower in vitro 
cytotoxicity and slightly better in vivo antitumor efficacy as compared to a model drug MMAE.  
However, the PDCs contributed to much lower weight loss in mice indicating lower side effects 
in vivo. 
This study demonstrated the feasibility of a Knob-Socket based rational design of novel 
peptides ligands in improving the identification of specific binding in comparison to the labor 
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Chapter 1: Introduction 
The pharmacological properties of a drug determine the resulting biological effects in 
patients.  These biological effects are generally produced by the interaction of the drug molecule 
with its receptors at the site of action.  The drug-target interaction efficacy remains undermined 
unless the drug gets delivered to the action site at a concentration that causes maximum 
therapeutic effect and minimum side-effects (1).  However, the activity of majority of the 
currently used pharmaceuticals is not based on their ability to accumulate specifically in the 
pathological site.  Typically, the active agent uniformly distributed throughout the body, has to 
cross numerous bio-barriers, like other organs, membranes and intracellular compartments before 
it reaches the site of action.  During this process, the molecule can get inactivated or exhibit 
undesirable effect in tissues not involved in the pathological process.  Consequently, the drug 
needs to be administered in high amounts to achieve the required therapeutic concentration in the 
pathological body compartment.  Thus, a large portion of the administered dose is just wasted in 
healthy normal tissues.  Moreover, this nonselective distribution, antigenic and/or cytotoxic 
drugs may lead to many negative side effects (2).  Drug targeting, i.e. predominant drug 
accumulation in the target organ or tissue, is one feasible option to tackle many of these 
challenges. 
1.1 Drug Targeting 
Drug targeting can be defined as the ability of a drug to selectively accumulate in the 
target organ or tissue in a manner that the drug concentration at the pathological site is high, 
while the concentration in the healthy non-target body parts is low, to prevent any peripheral 
toxic effect.  The key advantages of drug targeting are: (a) simplified drug administration 
protocol, (b) reduced quantity of drug required for therapeutic effect and lower cost of therapy, 
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and (c) achieving markedly increased drug concentration at target site without negative side 
reactions in non-target body compartments.  The same targeting strategy can also be applied to a 
great extent for the diagnostic molecules (3). 
The concept of drug targeting is not new.  It was first suggested by Paul Ehrlich almost a 
century ago when he introduced the hypothetical entity - “magic bullet” comprising of two 
components – first one to recognize and bind to the target and the second one which will impart 
the therapeutic effect.  In current concept the targeted drugs have three coordinated components: 
(a) the drug molecule, (b) the targeting moiety/ligand, (c) pharmaceutical carrier to deliver 
multiple drug molecules per targeting moiety.  Targeting can be applied on whole organ level, on 
cellular level specific for a certain organ, or even on the subcellular level such as, cell surface 
antigens (2, 4, 5). 
The most widely used targeting strategy is based on the knowledge that every organ or 
tissue contains certain molecules/biomarkers (antigens) that are specific for the organ of interest.  
To successfully deliver a drug to the target organ, another molecule (targeting moiety) can be 
used as a cargo unit which has the capability to specifically recognize and interact with the target 
antigen.  Based on this principle, many targeted drug delivery systems have been constructed that 
can deliver pharmaceuticals to various organs and tissues.  However in many cases, certain 
physical principles or physiological features of the target organ can be used for effective 
targeting of pharmaceuticals (6-9). 
1.2 Drug Targeting Strategies 
The principal drug targeting strategies which have been investigated in different 
experimental and clinical settings are: (a) direct application of the drug into the target organ or 
tissue, (b) passive accumulation of the drug molecule through leaky vasculature (passive 
21 
targeting), (c) physical targeting utilizing the differential pH and/or temperature at the target 
pathological compartment, or using paramagnetic drug carrier under the action of outside 
magnetic field, (d) targeting with the aid of ligand molecules (active targeting) having specific 
affinity towards the target site (2, 3). 
1.2.1 Direct application of drug into the target site.  In some cases, drug targeting can 
be achieved by simply administering the drug into the organ of interest. Although it sounds like a 
simple technique but the applicability is very limited and developing the formulation for direct 
application can be very complicated (2, 3).  Notable examples of this technique include intra-
articular application of methotrexate using liposomal formulation for arthritis (10), ophthalmic 
administration of carteolol loaded in nanoparticles to treat intraocular hypertension (11), and 
infusion of thrombolytic enzymes in coronary for the treatment of thrombus induced myocardial 
infarction (12). 
1.2.2 Passive targeting.  The blood vessel might become leaky under certain 
pathological states.  Highly permeable leaky vascular endothelium was observed in tumors (13), 
oxygen deficient areas of infarcted myocardium (14), and inflammation (3).  In those areas with 
high vascular permeability, relatively large nanoparticles like liposomes or micelles (size ranging 
from 10 to 500 nm) can penetrate and embedded inside interstitium.  These nanoparticles can 
carry the drug to the leaky area and release the drug by conventional carrier degradation.  The 
size of the nanocarriers can be adjusted to modulate the efficacy of the passive targeting system.  
This passive or spontaneous drug delivery is also known as ‘enhanced permeability and 
retention’ (EPR) effect (Figure 1.1) and is mostly used for targeting cancers (2, 15).  The 
prerequisite for this type of targeted delivery system is that the carriers used should be able to 
circulate in the blood for long enough duration to allow drug accumulation.  An excellent 
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example of this EPR based targeting is the commercial drug formulation, Doxil, which is long 
circulating polyethylene glycol (PEG) coated liposomes carrying doxorubicin (16).  Long 
circulating micellar system with smaller cut-off size was also shown to deliver the drug 
effectively into the tumor (17).  Long circulating liposomes may also be used to deliver drugs in 





Figure 1.1: Schematic representation of the passive targeting of drugs/drug carriers in leaky 




1.2.3 Physical targeting.  Different physical factors of both endogenous and exogenous 
origin have been explored for targeted drug delivery.  In the first case, targeting relies on 
pathological areas have different characteristics, like temperature, pH and/or redox potential 
when compared to normal areas.  It has been observed that the inflamed or neoplastic tissues 
generally exhibit lower pH and some degree of hyperthermia.  This allows the use of stimuli-
responsive drug transporters which degrade at higher temperature or lower pH than the normal 
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physiological range, releasing the entrapped drug.  Although the delivery systems are uniformly 
distributed throughout the body but they will only disintegrate and release the drug at the target 









Temperature-sensitive liposomes containing anti-cancer agent methotrexate have been 
shown to accumulate in tumors significantly faster when intravenously injected into tumor 
bearing mice.  This preferential accumulation was especially prominent when external heat was 
applied at the tumor region (20).  pH sensitive liposomes also achieved similar effects and are 
currently in use to deliver genetic materials and drugs to the target of interest (21). 
An example of drug targeting by external physical force is the magnetic drug delivery.  
To achieve this, drug is immobilized on a microcarrier with ferromagnetic properties.  When 
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administered intravenously, these carriers can accumulate in the area where an external magnetic 
field is applied.  The magnitude of accumulation will be dependent on the rate of blood flow and 
the applied magnetic field intensity (22).  Streptokinase was delivered in carotid arteries of 
experimental dogs for targeted lysis of thrombus by immobilizing the streptokinase on dextran 
coated iron oxide microparticles (23). 
1.2.4 Active targeting.  The drug targeting approaches described above are not universal. 
They have some crucial drawbacks.  Direct application of drug into the target organ/tissue can be 
technically challenging, or even the pathological site may be delocalized.  In many instances, the 
pathological area does not exhibit significant difference in terms of vascular leakiness, local pH 
or temperature, which makes the passive or physical targeting very difficult to achieve.  
Magnetic drug accumulation is also heavily dependent on the rate of blood flow in the target 
area.  The most common and universal strategy to convey specific affinity towards a target site to 
a nonspecific drug is the attachment of this drug with another entity (usually called a targeting 
moiety or ligand molecule) which can selectively recognize and bind to the target site.  Direct 
coupling of the drug to a targeting molecule is the simplest way to construct an active targeted 
drug delivery system (2) (Figure 1.3). 
Immunotoxins is one of the earliest examples of active drug targeting by direct coupling 
of a drug to a targeting moiety (24).  Reservoir type or particulate drug carriers have also been 
used to load the drug in active targeting.  This enables high drug loading, eliminates the need of 
covalent conjugation, and prevents enzymatic degradation of the drug. This also provides the 








1.3 Targeting Ligands/Moieties 
Targeting ligands can be roughly classified into the following categories: (a) small 
molecules (small molecule, vitamins, and carbohydrates), (b) antibodies, (c) protein domains, (d) 
nucleic acid based aptamers, and (e) peptides (26, 27).  These commonly used ligands are 
illustrated in Figure 1.4 in increasing order of their sizes (28-31). 
1.3.1 Targeting with small molecules.  One of the more customary targeting ligands are 
small molecules.  The main advantages of small molecule as the targeting ligand are good 
stability profile, straightforward conjugation technique, and low manufacturing cost, considering 
that it can be synthesized with high yield.  But so far there is no systematic protocol to develop 
such small molecule ligand and many of the already developed ligands do not show high binding 
affinity and specificity towards the target.  Vitamin H, also known as Biotin, was used for 
26 
superficial conjugation on nanoparticles having coated streptavidin for in vitro use.  The clinical 
use of this system is very limited because of immunogenicity coming from bacterial origin 
streptavidin (27). 
One of the most extensively investigated small molecule ligand for clinical application is 
folic acid (vitamin B6).  Folic acid binds to the endogenous folate receptors with high affinity.  
Folate receptors have been reported to be frequently upregulated in many cancer types.  A wide 
range of therapeutic or diagnostic agents have been conjugated to folate for selective drug 
delivery in tumor site, including chemotherapeutic drugs, protein therapeutics/toxins, gene 
therapy, oligonucleotides, radio-imaging agents, MRI agents, and drug-loaded nanoparticles (32, 
33). 
Another type of small molecule ligand which has been studied is benzamide, especially 
anisamide.  The receptor for benzamides is the sigma receptors.  Benzamides can target the 
drug/drug carrier to the tissues which express sigma receptors (34, 35). 
Carbohydrates that interact with certain cell surface receptors, can also be used as small 
molecule targeting ligand.  Targeting with carbohydrates uses the concept that endogenous lectin 
interacts with carbohydrates.  This type of targeting requires multiple carbohydrate interactions 
to establish strong binding.  Galactose or galactose-mimics can bind to asialoglycoprotein 
receptors, which are cell surface lectin receptors heavily expressed on hepatocytes.  Lex and 
ManLAM carbohydrates can be used to target the dendritic cells preferentially expressing DC-



























































































































































1.3.2 Targeting with antibodies.  Antibodies are serum glycoproteins produced by 
vertebrates, which bind selectively with antigens that induce their production.  These 
(Immunoglobulins -Igs) are Y shaped molecules.  Structurally, antibody contains two regions- 
two fragment antigen binding arms (Fab) and the stem (Fc fragment) connected to the Fabs 
through a hinge.  Based on the constant region, immunoglobulins can be classified into IgA, IgD, 
IgE, IgM, and IgG and symbolized as α, δ, ε, μ and γ, respectively.  Among them IgGs are most 
extensively used for therapeutic purpose.  Polyclonal antibodies are a heterogeneous mixture of 
antibodies.  They are produced from different clones of B cells and thus lack immunochemical 
similarity.  They are active towards multiple epitopes of a single antigen.  On the other hand, a 
monoclonal antibody is homogenous and is active against a single epitope.  Monoclonal 
antibodies (mAb) are produced from single clone of B cell of one animal (37, 38). 
There are different mechanisms by which antibodies impart therapeutic efficacy, but in 
many instances their activity does not produce a lasting effect.  Therefore, various strategies have 
been utilized to augment their activity.  Antibody-drug conjugate (ADC) is one such approach, 
which harness the antibody’s specificity and enable the targeted delivery a drug to the 
pathological site to enhance the activities of both antibody and drug molecule (39). 
Antibodies were originally considered as targeting moieties because of their availability 
and outstanding specificity as in vivo targeting ligand.  The extensive use of antibodies in in vivo 
therapeutics as targeting ligands resulted from many developments that overcame the limitation 
of cross-species immunogenicity.  Most of the current antibodies used for targeting are 
monoclonal and of murine origin.  But those produced from other species and polyclonal 
antibodies from rabbit have also been very effective.  Additionally, there are number of chimeric 
and humanized antibodies which have been used successfully for targeting.  Most of these 
29 
antibodies impart targeting by interacting with the extracellular domains of various cell surface 
proteins (27, 40-42). 
Two of the most important challenges of antibody-drug conjugates have been 
immunogenicity and purity.  The body may recognize antibodies as foreign entity and initiate 
compensatory immunogenic reaction.  And the conventional drug conjugation techniques often 
lead to heterogeneous product mixtures having different conjugation sites, antibody-drug molar 
ratios, and pharmacokinetic and safety profiles (27). 
1.3.3 Targeting with protein domains.  Targeting with antibody molecules have some 
intrinsic challenges as compared to small molecule targeting ligands.  Antibody molecules 
contain multiple light and heavy chains which are linked via disulfide bonds.  This sophisticated 
structure makes them difficult to express and the site-specific conjugation of the drug or drug 
carrier is a very complicated process.  In case of drug carriers, it is also very difficult to 
accommodate multiple antibody targeting ligands on the carrier surface due to the large size of 
the antibody molecules.  Additionally, it is a very time consuming and complicated task to 
engineer the full length antibody molecule to optimize its targeting efficiency (27). 
In general, an ideal protein targeting moiety should have: (a) sufficient solubility with 
minimal aggregation and high stability, (b) expression in bacterial system in high quantity and 
lower production costs, and (c) possess functional units that allow site specific conjugation (27). 
Numerous efforts have been made to reduce the size of the antibody molecule and create 
smaller binding units having affinity and specificity like an antibody.  Various protein scaffolds 
have been explored in order to find such compliant ligands, such as, antibody fragments, 
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knottins, avimers, affibodies, centyrins, Kunitz domains, adnectins, anticalins, darpins, affilins, 
etc. (31, 43, 44). 
1.3.4 Targeting with aptamers.  Aptamers are small single stranded nucleic acids, RNA 
or DNA.  They can display diverse structures and possess the potential to bind to many 
biochemical targets including small molecules and large proteins.  Since first developmental 
work, they have existed as a distinct class of targeting molecules.  Aptamer’s binding ability 
derives from its sequence; a 5’ and 3’ consensus region ranging from 12-20 nucleotide long 
which flanks a central part of entirely or partially randomized nucleotide sequence.  Aptamer’s 
advantages as the targeting moiety include: (a) aptamers can be synthesized with specific 
functional moieties like amino, sulfhydryl, carboxylate or aldehyde, at one end which allows 
simple site specific conjugation and prevents heterogeneous product mixtures, (b) they are 
generally non-immunogenic, (c) they are non-toxic, and (d) they can be modified for stability in 
circulation.  Aptamers can be synthesized chemically with low batch to batch variability.  
Because of their smaller size as compared to antibodies, they can form compact structures and 
bind to clefts, and enzymatic active sites more efficiently.  One major limitation of aptamer 
based targeted drug delivery in vivo has been the degradation of aptamers by nucleases in the 
biological system.  Attempts have been made to develop nuclease resistant aptamers by replacing 
2’-hydroxyl RNAs.  Aptamers resistant to nuclease activity which can bind to different cancer 
biomarkers (HER2, MUC1, HER3, EGF receptor, PSMA, VEGF receptor) have been 
successfully applied for various tumor targeting (27, 45-48). 
1.3.5 Targeting with peptides.  Short chains of amino acids linked by amide bonds are 
called peptides.  Peptides (except the cyclic ones) contain an N-terminal (amine end) and a C-
terminal (carboxyl end) (Figure 1.5).  Amino acid units in the peptide sequence are called 
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"residues" because either a proton (H+) from the amine side or a hydroxyl ion (OH−) from the 
carboxyl side, or both, are released as a water molecule during each amide bond formation.  
Peptides differ from proteins (also chains of amino acids) on the number of residues, and 
conventionally they contain less than 50 amino acids, while the larger ones are regarded as 
proteins.  Peptides consisting of 2-20 amino acids are referred to as oligopeptides and those 










Peptides offer one of the most attractive active targeting options.  Peptides are usually 
larger than small molecules but much smaller than antibodies.  It might be very challenging to 
design a small molecule ligand which will fit into a hydrophobic and shallow binding pocket.  As 
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a junction of the antibody and small molecule, peptides provide smaller size, as well as 
selectivity and high affinity (27). 
1.3.5.1 Advantages of peptide targeting ligands.  Since cellular targeting peptides have 
smaller size  (on an average < 30 amino acid long) and defined chemical structure, they have  
distinct advantages over antibodies, protein domains and oligosaccharides.  Few notable 
advantages are (51-57): 
 - Easy to manufacture by simple chemical synthesis 
 - Easily scalable and relatively inexpensive manufacturing procedure 
 - Peptides generally show good biocompatibility 
- Peptides can be easily manipulated for conjugation with chemical drugs, 
therapeutic genes or cytokines 
 - Some peptides have found to assist deep penetration inside tumor 
1.3.5.2 Tumor targeting peptides.  Cancer cells and the surrounding tumor 
microenvironment differ characteristically in terms expressing certain biomarkers.  These 
biomarkers make the tumor cells and the tumor vasculature susceptible for ligand mediated 
delivery of therapeutics or diagnostics (51).  Some of the recent tumor targeting approaches that 
uses peptide ligands are summarized below: 
1.3.5.2.1 Peptides targeting tumor vasculature.  Tumor vasculatures are significantly 
different than the normal blood vessels both morphologically and structurally (51, 58).  








Table 1.1  
 
List (non-exhaustive) of tumor vasculature targeting peptides 
 















Several tumor types 










F3 Nucleolin Blood 
vessels and 
tumor cells 




Esbp E-selectin Activated 
EC 
Human umbilical vein EC 
(HUVEC), human immortalized 
vascular EC (IVECs) 
IELLQAR  E-selectin  Mouse B16 melanoma and human 











MGC-803 human gastric cancer, 
BICR-H1 human breast cancer 
HTMYYHHYQ
HHL 










Table 1.1 (continued) 
Sequence Name Receptor Target cell Target tumor 




















MDA-MB-231 human breast 
adenocarcinoma, 4 T1 mouse 
mammary cancer, HUVEC non-





F3 Nucleolin Blood 
vessels and 
tumor cells 
















MMTV-PyMT transgenic breast 
cancer mice 































Table 1.1 (continued) 
Sequence Name Receptor Target cell Target tumor 




Mouse Tg model of pancreatic 
islet carcinogenesis 
CRGRRST RGR Angiogenic 
and pre-
malignant, 









Mouse Tg model of pancreatic 
islet carcinogenesis 










spontaneous prostate and breast 
cancer mouse models, KRIB 
osteosarcoma 






of the cervix and 
dysplasias and 
squamous cell 





1.3.5.2.2 Peptides targeting tumor cells.  Due to the better accessibility of peptides to 
blood vessel, targeting the tumor vasculature is far easier than the tumor cell targeting, several 











List (non-exhaustive) of tumor cell surface targeting peptides 
 
Sequence Name Receptor Target cell Target model 
YHWYGYTPQ
NVI 
GE11 EGFR Tumor cells SMMC-7721 human 
hepatoma cells 











Several tumor models 
CSDSWHYWC P1 VEGFR-3 Tumor cells HT29 human colon cancer, 
Y79 human retinoblastoma 
cancer 
CRTIGPSVC  Tf-R Tumor cells Human glioblastoma 
SPRPRHTLRLS
L 
B18 Tf-R Tumor cells Tf-R1-positive tumor cells 
and tissue 




 E- and N-
cadherin 
Tumor cells MCF-7 human breast 
carcinom, MDA-MB-435 
human breast carcinoma 
YCAREPPTRTF
AYWG 
EPPT1 uMUC-1 Tumor cells  
WHPWSYLWT
QQA (RP-1) 
 CD44 Tumor cells Gastric cancer 
RLVSYNGIIFF
LK 
A5G27 CD44v3 and 
CD44v6 
Tumor cells Various types of 
malignancies 




Table 1.2 (continued) 
















Tumor cells Melanoma Me6652/4 cells 
CSNRDARRC  Not 
determined 
Tumor cells HT-1376 human bladder 
transitional cell carcinoma 
CSSRTMHHC  Not 
determined 






 Human glioma 














TAMs TAMs harvested from CT-


















DCs CD11c + BMDDCs 
VTLTYEFAAG
PRD 
P-D2 CD11c/CD18 DCs CD11c + DCs 
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1.4 Peptide Discovery/Design Methods 
Peptide discovery/design methods can be broadly classified in to two categories: (a) 
structure free design methods, and (b) structure based methods (59). 
1.4.1 Structure free peptide design methods.  Cell surface binding peptides can be 
identified by creating and screening a combinatorial peptide library against a specific target 
molecule.  Combinatorial libraries can be subdivided into three major classes: (a) focused 
libraries of antibody, (b) one-bead one-compound peptide libraries (OBOC), (c) phage display 
libraries.  Although less commonly used, other biological approaches are bacterial, yeast, mRNA 
or ribosomal peptide display libraries (51, 60-63). 
1.4.1.1 Focused libraries of antibody.  Antibodies or their fragments have been used 
traditionally as targeting agents to deliver drugs or diagnostic molecules to the target organ or 
tissue.  Antibodies exhibit high binding affinity and selectivity towards the molecular target 
(antigen).  In fact, the hyper variable loops of the antibody’s variable domain, referred to as the 
complementarity determining regions (CDRs), are conventionally acknowledged to be 
responsible for antigen recognition (64).  A number of peptides having selective binding affinity 
towards the target antigen have been derived from the amino acid sequences of the CDRs (65).  
There are some major limitations of this technique.  (a) In many cases, it is difficult to prepare 
the crystals suitable for structural characterization of antibody fragment complexed with 
proteins/peptides.  (b) Recent studies suggest that the whole CDR sequence is not important for 
antigen binding, and residues outside of CDRs can contribute significantly in binding (66).  (c) 
Due to the lack of a universal CDR identification method, CDRs are not well defined and thus 
may not act as a very good surrogate of binding site (64).  Because of these limitations, one-
39 
bead–one-compound and phage display libraries are more commonly used techniques for 
identifying new peptide ligands. 
1.4.1.2 One-bead–one-compound libraries (OBOC).  This library screening method is 
based on a chemical technique first reported by Kit Lam and colleagues in 1991 to identify new 
peptide ligands for delivering therapeutics, imaging agents and protein inhibitors (67-69).  
OBOC libraries consist of resin beads (90 µm in size), each containing a distinct sequence of 
peptides that can be synthesized chemically using the standard solid phase peptide synthesis 
method.  In this method, beads are first divided into several equal amount portions.  A specific 
amino acid is coupled to each portion.  Then the amino acid loaded resin bead portions are 
combined, mixed thoroughly and again divided equally, followed by second amino acid 
coupling.  This is called split and pool steps.  These split and pool steps can be repeated 
sequentially to obtain a library of random peptide sequences (up to 107 sequences).  The beads 
are then screened in parallel by incubating with live fluorescent cells or pre-labeled target 
protein.  The beads which interact strongly with the cells are isolated by sorting.  And the beads 
having only a few cells bound to them are discarded.  Finally, the peptide on these positive beads 
is sequenced using Edman sequencing technique or by mass spectrometry (MS) after removing 
the coding tag from the bead. 
The advantages of OBOC technique are (60, 70, 71): 
- Allows the incorporation of non-natural amino acids, turned, cyclic or 
branched molecules 
- Allows the identification of proteolytic degradation resistant peptides 
- Screening can be performed with live cells which increases the possibility of 
identifying peptide ligands able to bind the native conformation of the target 
protein 
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- Binding affinity can be optimized by creating a secondary library from the 
first OBOC library 
A major limitation of this technique is the use of pre-labeled target protein for screening 
step.  Since the protein needs to be coupled with a fluorescent or chemical probe and purified 
before screening, there is a possibility that the protein might assume a non-native conformation 
which in turn would mislead the whole ligand identification process (51). 
1.4.1.3 Phage display libraries.  Phage display technique a biological approach that 
creates a random combinatorial peptide library (~ 108 peptides) (59).  It was first introduced in 
1985 by George Smith when bacteriophages containing filamentous DNA were engineered 
genetically to express foreign peptides (72).  In this technique, fragment of a foreign DNA is 
incorporated into the genome of the bacteriophage.  The foreign DNA fragment is placed in 
between the signal peptide coding sequences and the portion of the coat protein.  So, the 
incorporated exogenous peptide is displayed on the surface of the phage as a fusion with the coat 
protein.  The phage library is then incubated with the target protein, generally immobilized on 
solid support, followed by washing steps.  The washing steps remove the unbound phage 
particles.  Then the bound phage particles are collected using desired elution method.  The 
collected phage is amplified, and bio-panning step is carried out multiple times.  Finally, DNA 


































During past couple of decades, phage display technique had gone through many 
important changes and developments.  In the early days, peptide library screening used to be 
done with soluble target protein immobilized on solid support.  But later on live cells, tissue and 
live organisms have been utilized for selecting binding peptide candidates (54, 73, 74).  These 
relatively new bio-panning methods allows the target protein to remain in its functional and 
native conformation. 
Advantages of phage display technique are: 
- Peptides with high binding affinity and selectivity have been identified by this 
method (original form and the modified bio-panning) 
- Does not require prior knowledge of the structure or composition of the target protein 
However, one of the limitations of phage display technique is that the peptides can only 
contain natural amino acid residues (51).  Moreover, it is a trial-and-error based method which 
possess some degree of experimental complexity and can be relatively expensive. 
1.4.2 Structure based peptide design methods.  Structure based peptide design methods 
utilize the structural information obtained from the X-ray crystallographic structures of the target 
protein or even a related protein in some cases (59). 
1.4.2.1 Peptide design based on protein-protein interaction.  Peptide sequences 
identified by analyzing the protein-protein crystallographic interface constitute the primary 
source of structure-based peptide design (75).  The first peptide identified by this technique was 
a 36-amino acid long peptide, enfuvirtide, which got US-FDA (US Food and Drug 
Administration) approval as anti-HIV therapy.  It is considered as one of the most significant 
achievement in peptide therapeutics field (76). 
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Transcriptional factors generally have large protein-protein interfaces, making them very 
difficult to target by small molecules.  But peptides are being used now to target these 
transcriptional factors.  A breakthrough study reported the inhibition of downstream transcription 
of NOTCH signaling by directly inhibiting an important ternary complex (77). 
An alpha-helical peptide was derived from a co-factor (BH3 helix, pro-apoptotic in 
nature), and a technique called ‘peptide stapling’ was used to stabilize the inhibitory peptide 
binding (78).  Stapling stabilized the peptide binding to the anti-apoptotic protein, MCL-1.  
MCL-1 is a member of BCL-2 family proteins and has been found to be overexpressed in certain 
cancers (79). 
1.4.2.2 Peptide design based on protein-peptide interaction.  The structural information 
of the protein-peptide binding interface can be utilized to predict or model the interaction of a 
designed peptide with the protein.  This technique had been employed by three main ways:  
(1) A protein structure complexed with peptide ligand is used as the template and model a 
domain associated sequence by homology, followed by mutation in silico using a design 
(protein design) algorithm to change the amino acid side chains keeping the peptide 
backbone fixed (80, 81).  
(2) A protein peptide complex structure to model the peptide sequence by homology 
keeping the peptide backbone flexible.  This has been used to redesign the peptide 
structures from the PDZ domain for specificity (82).  Another approach that permits 
backbone flexibility was validated using 89 peptide complexes (83). 
(3) The protein structure is used while only the approximate binding site of the peptide 
ligand is known.  The algorithm, PepSpec, is not dependent on the peptide structural 
model, rather it requires only a single residue anchoring in the binding pocket.  It 
incorporates backbone movements in the target protein by ensemble modeling.  This 




1.4.2.3 Peptide design using protein docking and fragment-based docking.  This is the 
more typical method used to design peptides, combining the use of target protein structures (or 
homology model) with docking algorithms to derive peptide sequences for the selected site on 
the target.  There are techniques to structurally distinguish the assumed binding sites, for 
example, the use of geometric amino acid reliant predilections resulting from a number of 
binding modes (85).  A genetic algorithm in combination with Autodock, a popular docking 
algorithm, was used to design tetra-peptides for binding on a predefined hydrophobic pocket of 
the protein α-synuclein, which is implicated in aggregation diseases.  Experimental evaluation 
confirmed multiple binding peptides with micro-molar affinities in terms of dissociation constant 
(86). 
Another example uses the Gaussian Network Model for binding site identification, 
followed by docking a database of dipeptides pairwise using Autodock on the grid along a 
selected stretchy binding path.  This derives an optimal peptide for the a target surface (87). 
1.5 Aminopeptidase N (CD13) 
Aminopeptidase N (APN), also known as CD13, is Zn+2 dependent cell surface 
ectopeptidase.  CD13 consists of 967 amino acid residues.  It has a short N-terminal intracellular 
domain, a single transmembrane region, and a large extracellular domain which contains the 
active site (Figure 1.7).  CD13 can be found as monomer and dimers on the cell surface.  The PI 
of CD13 is approximately 5 and its molecular weight is 140-150 kDa.  CD13 is heavily 
glycosylated with carbohydrates that is at least 20% of the protein mass.  CD13 has at least five 
different isoforms with differential O-glycosylation sites (88-90). 
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Although, CD13 is widely expressed in different mammalian cells, such as myeloid cells, 
mast cells, antigen presenting cells, keratinocytes, epithelial cells of the small intestine, prostate, 
renal proximal tubules and bile duct canaliculi, it has been reported to be linked to the 
development of both normal and malignant cells.  In terms of normal physiological functions, 
CD13 plays crucial role in processing of peptide hormones, such as, neuropeptides, angiogenesis 
and inflammation associated chemokines, and angiotensin III and IV.  It preferentially degrades 
the peptide hormones or proteins having neutral N-terminal amino acids.  CD13 is also involved 
in cell adhesion and endocytosis.  CD13 also act as a viral receptor and may be associated in 
cholesterol turnover (88-96). 
While there is very little or no CD13 expression in normal vessels, it is overexpressed in 
angiogenic vessels of the neoplastic tissues.  CD13 has been found to be upregulated in other 
angiogenesis involved pathological conditions.  For example, it was shown that CD13 is 
overexpressed in cardiac angiogenesis in mouse model.  Different tumor cells also express or 
overexpress CD13 receptor.  In terms of malignant cell growth, CD13 is implicated in tumor cell 

















Figure 1.7: Structure of the human CD13 ectodomain.  Domain I, II, III, and IV are blue, green, 
magenta, and yellow, respectively.  Numbers designate the domain limits.  N-Linked 





1.5.1 CD13 as a target for cancer therapy and CD13 targeting ligand.  CD13 is 
overexpressed in many cancers like breast, kidney, prostate, ovarian, colon, gastric, pancreatic 
and thyroid cancer (91, 95).  A phage display study in mouse model identified that Asn-Gly-Arg 
(NGR) peptide sequence flanked by at least one amino acid at each end (NGR motif) can 
specifically interact with CD13 (98, 103).  Among the 5 identified isoforms of CD13, NGR motif 
can only bind to the CD13 isoform expressed exclusively on the tumor vasculature, but not 
normal CD13-rich tissues (97).  Some of the NGR motifs that have been identified to target 
tumor vasculature CD13 are cyclic CNGRC [CNGRC (C1-C5)] (disulfide linked), GNGRG, 
NGRAHA, cyclic KNGRE (head to tail), triazole linked cyclic NGR, and CVLNGRMEC (104, 
105).  CD13 targeted NGR peptide-based drugs which were under clinical trial are summarized 










Drug(s) Target(s) Status 
NCT00483080 NGR-hTNF Colorectal cancer Phase II 
NCT00484211 NGR-hTNF Hepatocellular carcinoma Phase II 
NCT00098943 NGR-hTNF Colorectal cancer/ Head and neck cancer/ 
Kidney cancer/ Unspecified adult solid 
tumor 
Phase I 
NCT00484276 NGR-hTNF Malignant pleural mesothelioma Phase II 




Table 1.3 (continued) 
Clinical trial 
number 
Drug(s) Target(s) Status 
NCT00878111 NGR-hTNF Solid tumors Phase I 
NCT01358084 NGR-hTNF / 
Placebo 
Advanced malignant pleural mesothelioma Phase II 
NCT01098266 NGR-hTNF / 
Placebo 
Malignant pleural mesothelioma Phase III 
NCT00483509 NGR-hTNF/ 
Doxorubicin 
Small cell lung cancer Phase II 
NCT00484341 NGR-hTNF/ 
Doxorubicin 





Advanced or metastatic ovarian cancer Phase II 
NCT00305084 NGR-hTNF/ 
Doxorubicin 





Ovarian cancer Phase II 
NCT00483093 NGR-hTNF/ 
Cisplatin 

















1.6 Statement of Problem 
Proteins, peptides, antibodies, carbohydrates, aptamers, and vitamins are the most 
commonly used ligands for drug.  Among them, peptides possess several advantages such as 
smaller size compared to antibodies, ease of large-scale synthesis by chemical methods and high 
target specificity.  Recent advances in robust chemical conjugation techniques are expected to 
increase their use in cancer diagnosis, imaging and therapy.  The most widely used strategy to 
identify a peptide ligand against a target is to screen peptide libraries created by phage display 
method.  Even though, several peptide ligands have been identified using phage display 
technology, this trial-and-error based technique is inherently time consuming and expensive.  On 
the other hand, the structure based computational peptide design methods utilize structural 
information obtained from crystallographic protein-protein interfaces.  The computational design 
method combines homology models or structural information with docking to develop new 
targeting peptides.  Various computational methods have been utilized to date for developing a 
number of peptide targeting ligands.  However, currently there is no rational approach to design 
peptide ligands based on the packing of the ligand amino acid residues at the target protein 
binding site. 
Therefore, a rational peptide design technique based on the clear mapping of amino acid 
side-chain packing arrangements between ligand and target proteins has distinct advantages.  In 
this study, a rational peptide design method was developed that clearly defines the packing of the 
ligand at the binding site of the receptor protein.  The method is based on a novel description of 
protein-packing known as Knob-Socket model that provides a simplified yet accurate 
representation of residue packing between two molecules.  In this study, tumor vasculature 
biomarker, CD13, was used as a model target receptor. 
50 
1.7 Hypothesis 
Peptide ligands can be designed using a rational method based on protein-protein 
interactions defined by Knob-Socket protein packing model for selective binding to target 
protein. 
1.8 Specific Aims 
The purpose of this dissertation research is to develop a rational method to design peptide 
ligands.  The peptides with specific binding ability to CD13 will be designed, synthesized and 
characterized.  The peptide ligands will be used as a binding moiety to design peptide-drug 
conjugate.  The research objectives will be achieved through the following specific aims: 
(1) To design peptides based on knob-socket analysis of the crystal structure.  Peptide 
ligands which can specifically bind to the CD13 are designed.   
(2) To perform molecular modeling studies, to determine the binding energy and binding 
site by Molecular Operating Environment (MOE) and AutoDock Vina software, 
respectively.  These parameters are used to select peptide ligand candidates for further in 
vitro evaluation. 
(3) To synthesize and characterize the peptides.  Peptides with and without FITC 
conjugation are synthesized for this purpose. 
(4) To demonstrate that the designed peptides exhibit specific binding affinity towards 
CD13 similar to the conventional peptide ligand, CNGRC (C1-C5).  These properties 
were tested by performing in-vitro binding affinity determination and cellular 
binding/uptake studies. 
(5) To show the applicability of the designed peptide drug conjugate, it’s in vitro and in 
vivo evaluations are performed.  Peptide drug conjugate with a cleavable linker to a 
model drug, MMAE, are prepared.  The in vitro cytotoxicity and in vivo tumor efficacy 





Chapter 2: Design and Screening of Peptide Ligands 
2.1 Introduction 
The world of medicine is moving fast towards precision and personalized care where 
drugs are being tailored according to individual variability, and delivered specifically to the 
diseased tissue (106).  One of the most popular strategies to enhance the therapeutic efficacy 
while minimizing the systemic toxicities has been the active drug targeting with the aid of 
specially designed ligand moieties (107-109). 
Antibodies, peptides and aptamers are some of the commonly used targeting molecules.  
Among these, peptides possess several attractive features such as, high target specificity, reduced 
likelihood of unintended immunogenic interactions, and smaller size leading to better tissue 
penetration and favorable pharmacokinetic properties (110, 111).  There are more than 60 
peptide drug products approved by US Food and Drug Administration, with additional 140 
peptide drugs in clinical trials and more than 500 therapeutic peptides in preclinical stage (112).  
Recent advances in robust chemical synthesis and conjugation techniques are expected to further 
increase the use of peptide-based molecules in diagnosis, imaging and therapy. 
Efficient design of high-affinity peptide ligands via rational methods has been a major 
obstacle to the development of this potential drug class (59).  The most widely adopted strategy 
to identify a new peptide ligand is phage display, where a large library of peptides is screened 
against a predetermined target (54, 113, 114).  This high throughput technique has been a 
powerful and versatile approach for peptide ligand identification, but it is inherently time 
consuming and resource demanding.  One relatively new peptide design methodology, the 
computational design method combines structural information with docking, to develop new 
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peptides (59).  Campa et al. reported the design of a novel type III Epidermal Growth Factor 
Receptor (EGFRvIII) binding peptide through hydropathic complementarity approach (115).  
Using the program ANIMOMAT, the peptide sequences were designed to bind EGFRvIII.  In 
2000, Park et al. published a study on the design of a peptidomimetic having comparable 
biological properties to those of an antibody (116).  This peptidomimetic was developed based 
on an analysis of the human epidermal growth factor receptor 2 (HER2/neu) - antibody (anti-
HER2/neu) co-crystal structure.  In another computer assisted in silico screening of a large 
virtual library of peptides by Song et al., selected a peptide ligand for EGFR binding (117).  
Generally, peptides derived from an analysis of the protein interface structure constitute the 
primary source of these designs (59).  However, none of them identify peptide ligands using a 
model that exactly defines the specific packing of the ligand residues within a structure’s binding 
interface.  Therefore, a rational peptide design technique based on the clear mapping of amino 
acid side-chain packing arrangements between ligand and target proteins has distinct advantages.  
In this regard, the Knob-Socket based approach (118-120) could help to reduce the development 
time by allowing rational and expeditious in-process optimization and provides plausible 
alternatives to the experimental high-resolution receptor protein-peptide complex structures. 
In this study, a rational peptide design method is investigated that clearly defines the 
packing of the ligand at the binding site of the receptor protein.  The method is based on a novel 
description of protein-packing known as Knob-Socket (KS) that provides a simplified yet 
accurate representation of residue packing between two molecules (118-120).  The KS model 
uses the precision of Voronoi Polyhedra/Delauney Tessellations to identify contacts (121, 122) 
and is described as a 4-residue tetrahedral motif, where a one-residue knob belonging to a 
secondary structure packs into a three-residue socket on another secondary structure (Figure 2.1).  
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The KS model also provides information about the propensities of the knobs that most likely can 
pack into a respective socket (Figure 2.2). 
We employed this rational method to design peptide ligands for a prototype target- tumor 
vascular endothelial CD13 (Cluster of Differentiation 13) receptor.  CD13 is a good prototype 
target for the present study since it has an established peptide ligand CNGRC (C1-C5), identified 
through a phage display study, which can serve as a direct comparison for the evaluation of 
designed peptides.  Additionally, this target allows a clean in vivo evaluation of the designed 
peptides as the endothelial cells of the tumor vasculature are readily accessible to the ligands, 
and the vascular endothelial cells are genetically more stable than the tumor cells in developing 
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(1) Two-dimensional representation of the knob–socket motif shows the three residues X, 
Y, and H in the socket are all packed against a knob residue B from the other helix.  
While the residues side chains all pack against each other, the hydrogen bond (broken red 
line) connects X and H.  Consecutive residues X and Y share a peptide bond (continuous 
black line).  Residues Y and H only pack with their side chains (broken black line). 
(2) The tetrahedral arrangement of the four-residue knob–socket motif.  The knob residue 
B contacts all the three socket residues only through side-chain. 
















































2.2.1 Peptide design. 
2.2.1.1 Confirming the peptide binding site on human CD13 (hCD13).  The crystal 
structure of porcine CD13 (pCD13) is available in complex with a peptide targeting ligand 
CNGRCG (C1-C5) [Protein Data Bank (PDB) ID: 4OU3] (125).  However, the crystal structure 
of human CD13 (hCD13) is only available in complex with the endogenous ligand ANG IV 
(PDB ID: 4FYS) (88).  To confirm the target site for the peptide ligand, PDB ID: 4FYS and PDB 
ID: 4OU3 were loaded in Molecular Operating Environment (MOE) software (Version 2013.08, 
Chemical Computing Group, Montreal, QC, Canada) with a solution phase AMBER10:EHT 
forcefield and R-field solvation model.  Non-binding portions of the protein structures were then 
deleted keeping only the binding site residues.  For hCD13, the amino acids are A191-A215, 
K340-L487 and R855-R908, and for pCD13, they are A186-T210, K335-L482 and R852-R905.  
The homology between the hCD13 and pCD13 binding sites were analyzed using the Align and 
Superpose functions in the MOE. 
2.2.1.2 Mapping the hCD13 – ANG IV binding interface.  The PDB file of hCD13 – 
ANG IV complex (PDB ID: 4FYS) was loaded in the UCSF (University of California, San 
Francisco) Chimera program package (126).  The program connected the sequences of hCD13 
and ANG IV together and renumbered all the amino acids for the whole complex.  DSSP 
(Dictionary of Secondary Structure of Proteins) program (127) was used to assign the secondary 
structure definition to the hCD13.  An in-house program named relative packing clique (RPC) 
was used to precisely define a set of all residues that contact each other and classify them based 
on contact order (128).  Contacts were calculated from a Voronoi polyhedra analysis (121) which 
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included side-chain-to-side-chain contacts and side-chain-to-main-chain contacts for all the 
residues.  In addition, contacts were considered for main-chain-to-main-chain contacts for all 
non-neighboring residues.  The resulting Delaunay tessellation defines a contact graph between 
residues (122).  Based on the calculated two-dimensional contact graph, all sockets and knobs 
formed on the binding interface were identified. 
2.2.1.3 Designing peptide ligands.  The sockets on the protein that took part in ligand 
binding along with some other free sockets were selected as the target site for the peptide 
ligands.  Peptides were then designed by selecting the amino acid residues having highest (or 
second highest) propensities towards the selected sockets on the target site (Table 2.1).  When 
the distance between two knob residues was far because of the physical separation between the 
two CD13 surface sockets, flanking amino acids were inserted to fill the gap.  A database of five 
amino acid (5-mer) long peptides was created using different combinations of amino acids from 
the list of highest (or second highest) propensity knobs.  A second database of eight amino acid 














































































































































2.2.2 Screening of the peptide ligands.  Peptide sequences were first screened from the 
initial database using the following predetermined criteria.  Peptides that have Glutamine at the 
N-terminal can easily condense to form pyroglutamate degradation products (129).  Peptides 
with Xaa-Proline residues at the N-terminal may lead to diketopiperazine formation (130).  And 
oxidation of Methionine produces sulfoxide amino acids (131).  Consequently, peptides with 
Glutamine or Xaa-Proline on the N-terminal, or Methionine in the sequence were discarded.  
Additionally, peptides containing same amino acids consecutively were also removed from the 
initial database.  The remaining peptides were constructed in MOE using the Molecule Builder 
tool, and energy minimization was performed using the AMBER10:EHT forcefield and R-field 
solvation model.  After loading the hCD13 – ANG IV complex (PDB ID: 4FYS) in MOE, the 
protein structure was prepared using the LigX function with the default setting except the 
receptor strength of 5000.  The glycan, solvent and buffer molecules as well as the endogenous 
ligand ANG IV were removed from the docking simulation.  Docking of the peptides was 
performed on the hCD13’s peptide binding site using Dock function with rigid receptor protocol.  
Timeout (seconds) and No. of Return Poses in the default Triangle Matcher Placement option of 
the docking window were configured to 500 and 2,000, respectively.  At the end of docking, 
MOE produced 100 possible conformations for each peptide and respective docking score for the 
complex of peptides and hCD13.  Potential peptide candidates were selected using the docking 
score from MOE.  The docking score function estimates the free energy of binding of the ligand 
from a given binding pose.  A low (negative) docking score indicates a stable system and thus a 
likely interaction between the receptor and ligand.  Further docking studies were performed 
using a second molecular modeling software – AutoDock Vina (132).  The hCD13 structure 
(PDB ID: 4FYS) was prepared using Dock Prep in UCSF Chimera.  The endogenous ligand 
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ANG IV, glycans, buffer and water molecules were removed.  The designed peptide structures 
along with the positive control CNGRC (C1-C5) peptide were generated in Chimera using Build 
Structure function with default settings.  The peptide structures were then prepared using Dock 
Prep and Minimize Structure functions.  AutoDockTools within MGLTools (version 1.5.6) were 
used to generate the PDBQT format files of the peptides and receptor.  The docking was 
performed using the methods described by Hauser and Windshügel (133) and in AutoDock Vina 
manual (http://vina.scripps.edu/manual.html).  The position of the grid box center was set at (x, 
y, z) = (101.98, 20.068, 18.861), and the xyz dimensions of the grid box were 80 Å, 62 Å and 62 
Å, respectively.  The exhaustiveness of the docking run was set at 100.  A small set of peptides 
were selected for further experimental evaluation based on the AutoDock Vina predicted binding 
sites. 
2.3 Results and Discussions 
2.3.1 Peptide design.  Porcine CD13 (pCD12) and human CD13 (hCD13) have high 
similarity of sequence (80% overall, 100% in the active site, 94% in the peptide-binding region) 
(134).  When the peptide-binding regions of hCD13 and pCD13 were aligned and superposed 
using MOE, the overall root-mean-square deviation (RMSD) was 0.833 Å, indicative of 
significant similarity in their binding site conformation (Figure 2.3).  The endogenous ligand 
ANG IV and the peptide ligand CNGRCG (C1-C5) were also observed to reside very close to 
each other (Figure 2.3).  This suggested that the location where ANG IV binds on hCD13 could 




















Figure 2.3: The binding sites of hCD13 & pCD13 aligned and superposed [Blue 
structure – hCD13, green coil – ANG IV, magenta structure – pCD13, yellow coil – 
CNGRCG (C1-C5)] 
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Using the Knob-Socket model, the complicated CD13 ligand binding interface (Figure 
2.4) can be simplified and made more intelligible by the two-dimensional map of quaternary 
packing interactions shown in Figure 2.5.  A clear picture of the peptide residues knobs from 
ANG IV packing into sockets on the hCD13 surface is represented.  There are nine sockets on 
hCD13 filled by the knob residues coming from ANG IV.  ANG IV also forms five sockets, 
which pack knobs from hCD13.  For the 5-mer peptide design, six out of the nine sockets and 
one additional free socket formed by residues Y441, R442, and A445 were selected as the target 
site surface for the designed peptides (Figure 2.6).  For the designed peptide ligand, positions 1, 
2 and 5 were chosen as knobs to pack into the binding sockets.  At position 1, knobs were chosen 
for 2 binding sites: one consisting of two sockets in the helix and another consisting of a socket 
from a coil region.  Position 2’s knob only comes from the helix, while position 5’s knob is a 
single socket, but at 2 possible positions.  Knobs with high propensities to interact with these 
sockets were chosen as the basis for the peptide sequences.  Because these sockets span between 
2 types of secondary structure that are 12 Å apart at closest approach, two residues (positions 3 
and 4 on the peptide) were necessary to bridge between the binding sites.  All possible 
combinations of the highest propensity knobs (Figure 2.6 inset table) produced thirty-two (32) 5-
mer peptide sequences (Table 2.2). 
For the 8-mer peptide design, all sockets from 5-mer design and two additional free 
socket formed by residues T860, S861 & I864, and S861, I864 & S865, respectively, were 
selected as the target site surface for the designed peptides (Figure 2.7).  In case of 8-mer peptide 
design, a total of 384 peptides (Table 2.3) were obtained using all possible combinations of the 




















Figure 2.4: Binding site of hCD13 with the endogenous 
















































































































































































































































































































































































































































































































































































































































































































5-mer peptide sequences 
 
AA# → 
1 2 3 4 5 
Peptide#↓ 
1 Q Y A P V 
2 Q Y A P Y 
3 Q Y P A V 
4 Q Y P A Y 
5 Q F A P V 
6 Q F A P Y 
7 Q F P A V 
8 Q F P A Y 
9 Q I A P V 
10 Q I A P Y 
11 Q I P A V 
12 Q I P A Y 
13 Q L A P V 
14 Q L A P Y 
15 Q L P A V 
16 Q L P A Y 
17 G Y A P V 
18 G Y A P Y 
19 G Y P A V 
20 G Y P A Y 
21 G F A P V 
22 G F A P Y 
23 G F P A V 
24 G F P A Y 
25 G I A P V 
26 G I A P Y 
27 G I P A V 
28 G I P A Y 
29 G L A P V 
30 G L A P Y 
31 G L P A V 







8-mer peptide sequences 
 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
33 Q Y A P V Y Y L 
34 Q Y A P V Y Y M 
35 Q Y A P V Y Y F 
36 Q Y A P V Y L L 
37 Q Y A P V Y L M 
38 Q Y A P V Y L F 
39 Q Y A P V Y F L 
40 Q Y A P V Y F M 
41 Q Y A P V Y F F 
42 Q Y A P Y V Y L 
43 Q Y A P Y V Y M 
44 Q Y A P Y V Y F 
45 Q Y A P Y V L L 
46 Q Y A P Y V L M 
47 Q Y A P Y V L F 
48 Q Y A P Y V F L 
49 Q Y A P Y V F M 
50 Q Y A P Y V F F 
51 Q Y P A Y V Y L 
52 Q Y P A Y V Y M 
53 Q Y P A Y V Y F 
54 Q Y P A Y V L L 
55 Q Y P A Y V L M 
56 Q Y P A Y V L F 
57 Q Y P A Y V F L 
58 Q Y P A Y V F M 
59 Q Y P A Y V F F 
60 Q Y P A V Y Y L 
61 Q Y P A V Y Y M 
62 Q Y P A V Y Y F 
63 Q Y P A V Y L L 
64 Q Y P A V Y L M 
65 Q Y P A V Y L F 
66 Q Y P A V Y F L 
67 Q Y P A V Y F M 
68 Q Y P A V Y F F 
69 Q F A P V Y Y L 




Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
71 Q F A P V Y Y F 
72 Q F A P V Y L L 
73 Q F A P V Y L M 
74 Q F A P V Y L F 
75 Q F A P V Y F L 
76 Q F A P V Y F M 
77 Q F A P V Y F F 
78 Q F A P Y V Y L 
79 Q F A P Y V Y M 
80 Q F A P Y V Y F 
81 Q F A P Y V L L 
82 Q F A P Y V L M 
83 Q F A P Y V L F 
84 Q F A P Y V F L 
85 Q F A P Y V F M 
86 Q F A P Y V F F 
87 Q F P A Y V Y L 
88 Q F P A Y V Y M 
89 Q F P A Y V Y F 
90 Q F P A Y V L L 
91 Q F P A Y V L M 
92 Q F P A Y V L F 
93 Q F P A Y V F L 
94 Q F P A Y V F M 
95 Q F P A Y V F F 
96 Q F P A V Y Y L 
97 Q F P A V Y Y M 
98 Q F P A V Y Y F 
99 Q F P A V Y L L 
100 Q F P A V Y L M 
101 Q F P A V Y L F 
102 Q F P A V Y F L 
103 Q F P A V Y F M 
104 Q F P A V Y F F 
105 Q I A P V Y Y L 
106 Q I A P V Y Y M 
107 Q I A P V Y Y F 
108 Q I A P V Y L L 
(continued)
70 
Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
109 Q I A P V Y L M 
110 Q I A P V Y L F 
111 Q I A P V Y F L 
112 Q I A P V Y F M 
113 Q I A P V Y F F 
114 Q I A P Y V Y L 
115 Q I A P Y V Y M 
116 Q I A P Y V Y F 
117 Q I A P Y V L L 
118 Q I A P Y V L M 
119 Q I A P Y V L F 
120 Q I A P Y V F L 
121 Q I A P Y V F M 
122 Q I A P Y V F F 
123 Q I P A Y V Y L 
124 Q I P A Y V Y M 
125 Q I P A Y V Y F 
126 Q I P A Y V L L 
127 Q I P A Y V L M 
128 Q I P A Y V L F 
129 Q I P A Y V F L 
130 Q I P A Y V F M 
131 Q I P A Y V F F 
132 Q I P A V Y Y L 
133 Q I P A V Y Y M 
134 Q I P A V Y Y F 
135 Q I P A V Y L L 
136 Q I P A V Y L M 
137 Q I P A V Y L F 
138 Q I P A V Y F L 
139 Q I P A V Y F M 
140 Q I P A V Y F F 
141 G Y A P V Y Y L 
142 G Y A P V Y Y M 
143 G Y A P V Y Y F 
144 G Y A P V Y L L 
145 G Y A P V Y L M 
146 G Y A P V Y L F 
147 G Y A P V Y F L 
(continued)
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Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
148 G Y A P V Y F M 
149 G Y A P V Y F F 
150 G Y A P Y V Y L 
151 G Y A P Y V Y M 
152 G Y A P Y V Y F 
153 G Y A P Y V L L 
154 G Y A P Y V L M 
155 G Y A P Y V L F 
156 G Y A P Y V F L 
157 G Y A P Y V F M 
158 G Y A P Y V F F 
159 G Y P A Y V Y L 
160 G Y P A Y V Y M 
161 G Y P A Y V Y F 
162 G Y P A Y V L L 
163 G Y P A Y V L M 
164 G Y P A Y V L F 
165 G Y P A Y V F L 
166 G Y P A Y V F M 
167 G Y P A Y V F F 
168 G Y P A V Y Y L 
169 G Y P A V Y Y M 
170 G Y P A V Y Y F 
171 G Y P A V Y L L 
172 G Y P A V Y L M 
173 G Y P A V Y L F 
174 G Y P A V Y F L 
175 G Y P A V Y F M 
176 G Y P A V Y F F 
177 G F A P V Y Y L 
178 G F A P V Y Y M 
179 G F A P V Y Y F 
180 G F A P V Y L L 
181 G F A P V Y L M 
182 G F A P V Y L F 
183 G F A P V Y F L 
184 G F A P V Y F M 
185 G F A P V Y F F 
186 G F A P Y V Y L 
(continued)
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Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
187 G F A P Y V Y M 
188 G F A P Y V Y F 
189 G F A P Y V L L 
190 G F A P Y V L M 
191 G F A P Y V L F 
192 G F A P Y V F L 
193 G F A P Y V F M 
194 G F A P Y V F F 
195 G F P A Y V Y L 
196 G F P A Y V Y M 
197 G F P A Y V Y F 
198 G F P A Y V L L 
199 G F P A Y V L M 
200 G F P A Y V L F 
201 G F P A Y V F L 
202 G F P A Y V F M 
203 G F P A Y V F F 
204 G F P A V Y Y L 
205 G F P A V Y Y M 
206 G F P A V Y Y F 
207 G F P A V Y L L 
208 G F P A V Y L M 
209 G F P A V Y L F 
210 G F P A V Y F L 
211 G F P A V Y F M 
212 G F P A V Y F F 
213 G I A P V Y Y L 
214 G I A P V Y Y M 
215 G I A P V Y Y F 
216 G I A P V Y L L 
217 G I A P V Y L M 
218 G I A P V Y L F 
219 G I A P V Y F L 
220 G I A P V Y F M 
221 G I A P V Y F F 
222 G I A P Y V Y L 
223 G I A P Y V Y M 
224 G I A P Y V Y F 
225 G I A P Y V L L 
(continued)
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Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
226 G I A P Y V L M 
227 G I A P Y V L F 
228 G I A P Y V F L 
229 G I A P Y V F M 
230 G I A P Y V F F 
231 G I P A Y V Y L 
232 G I P A Y V Y M 
233 G I P A Y V Y F 
234 G I P A Y V L L 
235 G I P A Y V L M 
236 G I P A Y V L F 
237 G I P A Y V F L 
238 G I P A Y V F M 
239 G I P A Y V F F 
240 G I P A V Y Y L 
241 G I P A V Y Y M 
242 G I P A V Y Y F 
243 G I P A V Y L L 
244 G I P A V Y L M 
245 G I P A V Y L F 
246 G I P A V Y F L 
247 G I P A V Y F M 
248 G I P A V Y F F 
249 Q Y A P V Y E L 
250 Q Y A P V Y E M 
251 Q Y A P V Y E F 
252 Q Y A P Y V E L 
253 Q Y A P Y V E M 
254 Q Y A P Y V E F 
255 Q Y P A Y V E L 
256 Q Y P A Y V E M 
257 Q Y P A Y V E F 
258 Q Y P A V Y E L 
259 Q Y P A V Y E M 
260 Q Y P A V Y E F 
261 Q F A P V Y E L 
262 Q F A P V Y E M 
263 Q F A P V Y E F 
264 Q F A P Y V E L 
(continued)
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Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
265 Q F A P Y V E M 
266 Q F A P Y V E F 
267 Q F P A Y V E L 
268 Q F P A Y V E M 
269 Q F P A Y V E F 
270 Q F P A V Y E L 
271 Q F P A V Y E M 
272 Q F P A V Y E F 
273 Q I A P V Y E L 
274 Q I A P V Y E M 
275 Q I A P V Y E F 
276 Q I A P Y V E L 
277 Q I A P Y V E M 
278 Q I A P Y V E F 
279 Q I P A Y V E L 
280 Q I P A Y V E M 
281 Q I P A Y V E F 
282 Q I P A V Y E L 
283 Q I P A V Y E M 
284 Q I P A V Y E F 
285 G Y A P V Y E L 
286 G Y A P V Y E M 
287 G Y A P V Y E F 
288 G Y A P Y V E L 
289 G Y A P Y V E M 
290 G Y A P Y V E F 
291 G Y P A Y V E L 
292 G Y P A Y V E M 
293 G Y P A Y V E F 
294 G Y P A V Y E L 
295 G Y P A V Y E M 
296 G Y P A V Y E F 
297 G F A P V Y E L 
298 G F A P V Y E M 
299 G F A P V Y E F 
300 G F A P Y V E L 
301 G F A P Y V E M 
302 G F A P Y V E F 
303 G F P A Y V E L 
(continued)
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Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
304 G F P A Y V E M 
305 G F P A Y V E F 
306 G F P A V Y E L 
307 G F P A V Y E M 
308 G F P A V Y E F 
309 G I A P V Y E L 
310 G I A P V Y E M 
311 G I A P V Y E F 
312 G I A P Y V E L 
313 G I A P Y V E M 
314 G I A P Y V E F 
315 G I P A Y V E L 
316 G I P A Y V E M 
317 G I P A Y V E F 
318 G I P A V Y E L 
319 G I P A V Y E M 
320 G I P A V Y E F 
321 Q L A P V Y Y L 
322 Q L A P V Y Y M 
323 Q L A P V Y Y F 
324 Q L A P V Y L L 
325 Q L A P V Y L M 
326 Q L A P V Y L F 
327 Q L A P V Y F L 
328 Q L A P V Y F M 
329 Q L A P V Y F F 
330 Q L A P Y V Y L 
331 Q L A P Y V Y M 
332 Q L A P Y V Y F 
333 Q L A P Y V L L 
334 Q L A P Y V L M 
335 Q L A P Y V L F 
336 Q L A P Y V F L 
337 Q L A P Y V F M 
338 Q L A P Y V F F 
339 Q L P A Y V Y L 
340 Q L P A Y V Y M 
341 Q L P A Y V Y F 
342 Q L P A Y V L L 
(continued)
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Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
343 Q L P A Y V L M 
344 Q L P A Y V L F 
345 Q L P A Y V F L 
346 Q L P A Y V F M 
347 Q L P A Y V F F 
348 Q L P A V Y Y L 
349 Q L P A V Y Y M 
350 Q L P A V Y Y F 
351 Q L P A V Y L L 
352 Q L P A V Y L M 
353 Q L P A V Y L F 
354 Q L P A V Y F L 
355 Q L P A V Y F M 
356 Q L P A V Y F F 
357 Q L A P V Y E L 
358 Q L A P V Y E M 
359 Q L A P V Y E F 
360 Q L A P Y V E L 
361 Q L A P Y V E M 
362 Q L A P Y V E F 
363 Q L P A Y V E L 
364 Q L P A Y V E M 
365 Q L P A Y V E F 
366 Q L P A V Y E L 
367 Q L P A V Y E M 
368 Q L P A V Y E F 
369 G L A P V Y Y L 
370 G L A P V Y Y M 
371 G L A P V Y Y F 
372 G L A P V Y L L 
373 G L A P V Y L M 
374 G L A P V Y L F 
375 G L A P V Y F L 
376 G L A P V Y F M 
377 G L A P V Y F F 
378 G L A P Y V Y L 
379 G L A P Y V Y M 
380 G L A P Y V Y F 
381 G L A P Y V L L 
(continued)
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Table 2.3 (continued) 
AA# → 
1 2 3 4 5 6 7 8 
Peptide#↓ 
382 G L A P Y V L M 
383 G L A P Y V L F 
384 G L A P Y V F L 
385 G L A P Y V F M 
386 G L A P Y V F F 
387 G L P A Y V Y L 
388 G L P A Y V Y M 
389 G L P A Y V Y F 
390 G L P A Y V L L 
391 G L P A Y V L M 
392 G L P A Y V L F 
393 G L P A Y V F L 
394 G L P A Y V F M 
395 G L P A Y V F F 
396 G L P A V Y Y L 
397 G L P A V Y Y M 
398 G L P A V Y Y F 
399 G L P A V Y L L 
400 G L P A V Y L M 
401 G L P A V Y L F 
402 G L P A V Y F L 
403 G L P A V Y F M 
404 G L P A V Y F F 
405 G L A P V Y E L 
406 G L A P V Y E M 
407 G L A P V Y E F 
408 G L A P Y V E L 
409 G L A P Y V E M 
410 G L A P Y V E F 
411 G L P A Y V E L 
412 G L P A Y V E M 
413 G L P A Y V E F 
414 G L P A V Y E L 
415 G L P A V Y E M 





2.3.2 Screening of the peptide ligands.  Using the predetermined criteria (previously 
discussed in the Method section) eight (8) 5-mer peptides were selected from the initial 
sequences and subjected to MOE docking.  These eight (8) 5-mer peptides were ranked 
according to their MOE docking scores (Table 2.4).  In case of 8-mer peptide design, the 
predetermined criteria led to forty (40) 8-mer peptide sequences.  These 40 peptides were 
subjected to MOE docking and the top ten ranking peptides (top 25% based on the MOE docking 
score) are listed in Table 2.4. 
An additional docking studies with AutoDock Vina were performed for all eight (8) of 
the 5-mer peptides and top 25% (10) of the 8-mer peptides based on MOE docking score 
ranking.  Of these, AutoDock Vina predicted that three designed peptides [two 5-mer (PEP20, 
GYPAY and PEP24, GFPAY), and one 8-mer (PEP173, GYPAVYLF)] could bind to the 
intended active site of hCD13 similar to the positive control CNGRC (C1-C5) peptide ligand 
(NGR-2C) (Figure 2.8 & Table 2.4).  These three (3) peptides along with two (2) other 
nonspecific peptides (PEP293, GYPAYVEF and PEP308, GFPAVYEF; as negative controls) 


















Figure 2.8: Peptides at hCD13 binding site after docking with AutoDock Vina.  Green coil: 





















1 20 G  Y P A Y - - - -13.9095 On active site 
2 24 G  F P A Y - - - -11.9234 On active site 
3 19 G  Y P A V - - - -11.7211 
Distant from 
active site 
4 27 G  I P A V - - - -11.6586 
Distant from 
active site 
5 32 G  L P A Y - - - -11.5135 
Distant from 
active site 
6 28 G  I P A Y - - - -11.3576 
Distant from 
active site 
7 31 G  L P A V - - - -10.7643 
Distant from 
active site 
8 23 G  F P A V - - - -10.7205 
Distant from 
active site 
- NGR-2C C 
 
N G R 
C(1-
5) 
- - - -11.2815 On active site 
 
8-mer peptides 
1 296 G 
 
Y P A V Y E F -16.9475 
Distant from 
active site 
2 293 G 
 


















Binding Site Peptide↓ 
 
3 317 G 
 
I P A Y V E F -16.6490 
Distant from 
active site 
4 389 G 
 
L P A Y V Y F -16.5394 
Distant from 
active site 
5 209 G 
 
F P A V Y L F -16.4622 
Distant from 
active site 
6 161 G 
 
Y P A Y V Y F -16.3548 
Distant from 
active site 
7 308 G 
 
F P A V Y E F -16.2962 
Distant from 
active site 
8 173 G 
 
Y P A V Y L F -16.2385 
On active site 
9 387 G 
 
L P A Y V Y L -16.0129 
Distant from 
active site 
10 245 G 
 











Chapter 3: Synthesis and Characterization of Molecules 
3.1 Introduction 
Peptides are made by coupling the carboxyl group of one amino acid to the amino group 
of another.  The classical peptide synthesis approach is the solution phase synthesis.  However, 
most labs have replaced it by solid phase synthesis technique.  The solid phase peptide synthesis 
(SPPS) was developed by Bruce Merrifield in 1963 and since then it has been widely used for 
peptide synthesis in academic labs and industry.  The advantages of SPPS are: (a) can be used to 
synthesize peptides that cannot be made by bacteria, (b) it allows the incorporation of 
complicated moieties in peptide structure, (c) generally yields peptides with high purity.  The 
limitations of SPPS are: (a) low yield as it carries many cycles of de-protection and coupling for 
each amino acid in the sequence, (b) sequence dependent synthetic difficulty (135). 
In SPPS a peptide chain is created backwards starting from the C-terminal towards the N-
terminal end on a solid resin support by creating amide bonds between amino acids (136).  The 
SPPS can be carried out manually or with the aid of automatic synthesizer, especially if the 
sequence is relatively long (137). 
In this study, Wang resin (typically preloaded with starting C-terminal amino acid) was 
selected as the solid support resin due to the compatibility with FITC-conjugation and 
straightforward method.  Wang resin normally holds strong attachment to the peptides until 
cleaved by trifluoroacetic acid (TFA).  In SPPS the solid resins and the synthesized peptides 
attached to them do not pass through the filter in the synthesis vessel.  
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Amino acid side chains contain different types of functional groups making them 
susceptible to side chain reactions during peptide synthesis.  Consequently, protecting groups are 
required to obtain the desired peptide molecule.  Benzyl (Bzl) or tert-butyl (tBu) groups are the 
most commonly used protecting groups (138).  But various other protecting groups are also used 
during SPPS of a peptide depending on peptide sequence and N-terminal protecting moiety.  
Side chain protecting groups are permanent protecting groups.  They tolerate multiple cycles of 
chemical reactions during the SPPS.  They are removed at the end stage during cleavage of the 
peptide chain from the resin by treating with strong acids like TFA. 
Peptide synthesis will be started with Wang resin (chlorotrityl resin in case of CNGRC 
(C1-C5) peptide) preloaded with the C-terminal amino acid having its N-terminal protected with 
Fmoc group.  Fmoc stands for 9-Fluorenylmethoxycarbonyl which is the temporary N-terminal 
protecting group.  The next steps involves creating the peptide chain by de-protecting the 
terminal amine and conjugation of next amino acid (Figure 3.1). 
Fmoc can be removed by treating the resin with mild basic solution (20% piperidine in 
DMF) (Figure 3.2).  The next amino acid is coupled to the peptide sequence by adding the amino 
acid together with carbodiimide, such as dicyclohexylcarbodiimide (DCC) or 
diisopropylcarbodiimide (DIC) which activates the C-terminal carboxylic group of that amino 
acid.  Carbodiimide reacts with available carboxyl group and create a highly reactive O-
acylisourea intermediate, which is immediately substituted by nucleophilic attack by the 
deprotected primary amine group on the N-terminal of the elongating peptide chain and forms 
amide bond (peptide bond) (Figure 3.3).  However, reactive O-acylisourea intermediates may 
lead to racemization of the amino acids.  Thus, racemic suppressors like 1-hydroxybenzotriazole 
(HOBt) that react with the O-acylisourea intermediate are generally added to eliminate 
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racemization (Figure 3.3).  The newly formed N-terminal of the peptide is then deprotected again 
and coupled to the next amino acid.  Kaiser test can be performed to monitor and confirm the 
completion of each deprotection and coupling steps (139) (Figure 3.4).  This deprotection and 
coupling cycle is repeated until the full peptide sequence is created. 
When all the amino acid couplings are complete, the peptide is cleaved from the solid 
resin.  All sidechain protecting groups and the C-terminal attachment to the solid support are 
removed by acidic cleavage cocktail containing TFA.  Peptide is normally isolated from the 
cocktail by using ice cold diethyl ether.  Then the peptide is characterized by mass 













































































Fmoc-amino acid-Wang resins, Fmoc-amino acid-2-chlorotrityl resins, Fmoc-amino 
acids, Boc-amino acids, Fmoc-aminohexanoic acid, N, N′-diisopropylcarbodiimide (DIC), 
diisopropylethylamine (DIPEA), triisopropylsilane (TIS), N-hydroxybenzotriazole (HOBT) were 
purchased from Chem-Impex International Ltd (Wood Dale, IL, USA).  Trifluoro acetic acid 
(TFA) was obtained from Acros Organics (New Jersey, USA).  Diethyl ether, N, N′-
dimethylformamide (DMF) and dichloromethane (DCM) were purchased from Fisher Scientific 
(Pittsburgh, PA, USA).  Fmoc-Lys(ivDde)-Wang resin was obtained from Peptides International 
(Louisville, KY, USA).  FITC was obtained from AnaSpec (Fremont, CA, USA). 
3.3 Methods 
3.3.1 Synthesis of peptides.  The selected designed peptides (PEP20, GYPAY; PEP24, 
GFPAY; and PEP173, GYPAVYLF), CNGRC (C1-C5) peptide (NGR-2C), and GARAG 
peptide (negative control) were synthesized by standard solid phase synthesis method (0.2 to 0.4 
mmol scale).  Coupling of subsequent amino acids was performed with 3 to 5 fold excess of 1-
hydroxy-benzotriazole (HOBt) and diisopropyl-carbodiimide (DIC).  Each coupling was done 
for 3 hours, followed by Kaiser test to confirm the completeness of reaction.  Fmoc group was 
removed in each step by treating the resins was solution of 20% piperidine in DMF.  Kaiser tests 
were also performed after each deprotection step.  Boc protected amino acids were used only for 
the last N-terminal amino acids to eliminate the necessity of last Fmoc deprotection step.  
Cleavage of the peptides were done by treating the resins with trifluoroacetic acid – water – 
triisopropylsilane (95: 2.5: 2.5) cocktail for 3 hours.  The obtained TFA-peptide solution was 
cooled and evaporated under nitrogen flow until it became thick viscous oily liquid.  Ice cold 
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ether was added to the oily liquid to precipitate the peptide.  The peptides are then freeze dried 
and stored in −20° C freeze until further use. 
In case of CNGRC (C1-C5) peptide, the synthesis scheme started with Fmoc-L-Cys(Trt)-
2-chlorotrityl resin and cyclization was achieved by the formation of 1-5 disulfide bond using 
iodine in dimethylformamide (DMF) at 0° C for 2 hours (140).  The other steps were same as 
described above. 
3.3.2 Synthesis of FITC conjugated peptides.  The synthesis was started with Fmoc-
Lys(ivDde)-Wang resin to maintain simple solid phase synthesis method and easily place the 
FITC probe towards C-terminal side (141) (Figure 3.5).  A spacer (e.g. 6-aminohexanoic acid/ 
Ahx) was added between the peptide sequence and the lysine residue at the C-terminal using 
same DIC/HOBt coupling method.  After coupling the last amino acid (Boc protected) at the N-
terminal, the resins were treated with 2% hydrazine to remove the ivDde group from the C-
terminal lysine.  Then FITC was coupled to the exposed primary –NH2 group on the side chain 
of lysine (142).  Finally, the FITC labelled peptides were cleaved from the resin using 
trifluoroacetic acid – water – triisopropylsilane (95 : 2.5 : 2.5) cocktail.  After synthesis, the 
conjugated peptides were freeze-dried and stored in −20° C freeze until further use. 
3.3.3 HPLC analysis of the synthesized molecules.  The purity of the synthesized 
molecules was determined using high pressure liquid chromatography (HPLC) (Agilent 1100).  
The column used was Agilent Zorbax C18, 5 μ, 4.6×150 mm, and the wavelengths used for 
detection were 210, 254 and 280 nm.  The samples were eluted with a mobile phase consisting of 
water with 0.1% TFA (A) and acetonitrile with 0.1% TFA (B) using a linear gradient from 10 to 
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90% B over 30 to 35 minutes, at 1.0 mL/min flow rate.  The purified peptides were freeze dried 
and stored at -20° C. 
3.3.4 Mass spectrometry analysis of the synthesized molecules.  Formation of the 
synthesized molecules were confirmed by Electron Spray Ionization Mass Spectrometry (ESI-
MS, API 3000 Mass Spectrometer).  Samples were prepared in water/methanol or 























































3.4 Results and Discussion 
All the peptides were successfully synthesized using standard solid phase synthesis 
method.  These peptides were used for in vitro binding studies with CD13 protein by enzymatic 
activity inhibition studies.  The fluorescent dye, FITC, was successfully conjugated with the 
peptides  and used incell surface binding and confocal microscopy studies.  The physicochemical 
properties of the peptides are shown in figures 3.6, 3.11, 3.16, 3.21, 3.26, 3.31, and 3.34. 
All the molecules were characterized by ESI MS.  The MS results showed the desired 
molecular weight of the synthesized molecules.  The peptides were observed as singly charged 
species and the peptides with FITC were observed as doubly charged species.  The MS 
confirmed the formation of all the molecules as shown in figures 3.7, 3.8, 3.12, 3.13, 3.17, 3.18, 
3.22, 3.23, 3.27, 3.28, 3.32, and 3.35. 
Reverse phase HPLC of the molecules was performed at 210 nm, 254 nm and/or 280 nm 
wavelength.  Samples were eluted and collected to identify and confirm the molecular weight by 
MS.  The desired peaks were finally separated and purified using a semi-preparative column.  
The purities of the synthesized molecules were in the range of 93% to 98% (Table 3.1).  The 
HPLC chromatograms of the purified molecules are shown in figures 3.9, 3.10, 3.14, 3.15, 3.19, 
3.20, 3.24, 3.25, 3.29, 3.30, 3.33, and 3.36.  
Calculated and observed molecular weights along with the purity of the synthesized 













HPLC Purity (%) 
PEP20 (GYPAY) 570.25 570.3 97.3 
PEP20-FITC 1200.46 601.0 97.7 
    
PEP24 (GFPAY) 554.25 554.3 97.4 
PEP24-FITC 1184.47 592.9 97.8 
    
PEP173 (GYPAVYLF) 929.47 929.8 93.0 
PEP173-FITC 1569.68 780.6 96.2 
    
NGR-2C [CNGRC(1-5)] 550.18 550.2 95.0 
NGR-2C-FITC 1180.39 590.9 96.6 
    
GARAG 431.23 431.3 95.0 
GARAG-FITC 1061.44 531.4 96.4 
    
PEP293 (GYPAYVEF) 945.42 945.7 98.0 
    
















































































































































































































































































































































































































































































































































































Sequence: CNGRC (C1-C5) 
MW: 549.63 









































































































































































































































































































































































































































































































































































































Chapter 4: Characterization of CD13 Binding Properties of the Peptide Ligands 
4.1 Introduction 
An important concept of both theoretical studies and drug/ligand development is the 
quantification of ligand binding to the target receptor.  The key aspects of ligand receptor 
interactions include binding affinity, binding specificity, binding site, target conformations, 
ligand efficiency, and binding thermodynamics.  Every aspect of these ligand receptor 
interactions can be studied by different ligand binding assays.  There are numerous ligand 
binding assays, such as labeled ligand, label free, structure based, thermodynamic, and whole 
cell ligand binding assays (143). 
Labeled ligand binding assays use different types of probes like fluorescent, radioisotope 
or bioluminescent molecules attached to the ligand molecule.  The major limitation of this type 
of assay is that the labeling of the ligand with a probe can lead to unwanted changes in binding 
properties of the ligand.  The most widely used label free ligand binding assay, surface plasmon 
resonance (SPR), has low sensitivity to binding prompted conformational changes in receptor 
protein, and it does not generally provide any information about the binding site of the ligand.  
Structure based ligand binding assays like Nuclear magnetic resonance (NMR) or X-ray 
crystallography are typically very expensive and thus may not be used as routine binding assays.  
The thermodynamic binding assays, such as, Isothermal titration calorimetry (ITC), require large 
amount of sample.  The whole cell ligand binding assays might not be suitable for relatively 
smaller ligand molecules like peptides (143). 
The prototype target receptor of this study, CD13 (Aminopeptidase N), is an enzyme.  
The peptide ligand binding site overlaps with the enzymatic active site of CD13 (125, 134).  
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Therefore, binding of the peptide ligands at the intended binding site should inhibit the 
enzymatic activity of CD13 and the binding affinity can be quantified in terms of the equilibrium 
dissociation constant (Ki for enzyme inhibition) (125, 144-146).  Importantly, this enzyme 
inhibition assay could also provide the information about the binding sites of the peptide ligands. 
Enzymatic activity starts with the reversible binding of a substrate (S) to the free enzyme 
(E) to form ES complex leading to free enzyme and product (P). 
𝐸 𝑆 ↔ 𝐸𝑆 → 𝐸 𝑃 
The rate or velocity (v) of an enzymatic reaction is measured either as the disappearance 








Under steady state condition the reaction velocity (v) can be determined from the slope of 
a linear plot of [P] or [S] vs time. 
Steady state enzyme velocity can be described as a saturable function of substrate 





Vmax is the maximum velocity at infinite substrate concentration.  Km is the kinetic 
constant commonly referred to as Michaelis constant.  Km is the substrate concentration at which 
the reaction velocity is half of the maximum velocity. 
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A typical plot of reaction velocity vs substrate concentration at steady state is presented 























Thus, a plot of 1/v vs 1/[S] will produce a straight line with slope of Km/Vmax, y-intercept 
of 1/Vmax, and x-intercept of -1/KM (figure 4.2).  Such plots are referred to as double reciprocal 















Figure 4.3: Enzymatic reaction equilibrium in presence or absence of inhibitor 
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I is the inhibitor, EI is the enzyme-inhibitor complex and ESI is the enzyme-substrate-
inhibitor complex.  kcat is the first-order rate constant for the reaction product formation step.  α 
is a constant that defines the degree to which the affinity of the enzyme (for substrate) is affected 
by inhibitor binding.  α > 1, if  EI complex decreases the affinity of the enzyme for substrate; α = 
1, if there is no change in substrate affinity; and α < 1, if the affinity of the enzyme for substrate 
is increased by the formation of EI complex.  Ki is the equilibrium dissociation constant for EI 
complex and αKi is the equilibrium dissociation constant for ESI complex.  There are three 
potential modes of inhibitor interactions with enzymes: (a) competitive inhibitors, (b) 
noncompetitive inhibitors, (c) uncompetitive inhibitors (147) (Figure 4.4).  Competitive 
inhibitors bind only to the free enzyme (α = ∞).  Noncompetitive inhibitors bind to both free 
enzyme and the enzyme-substrate complex (α > 1, when inhibitor binds with the free enzyme 
with greater affinity; α = 1, when inhibitor binds with the free enzyme and the enzyme substrate 
complex with equal affinity; and α < 1, when inhibitor binds with the enzyme-substrate complex 























Figure 4.4: Different enzyme inhibition modalities along with equations.  (A) Competitive 
inhibition, (B) noncompetitive inhibition; (C) uncompetitive inhibition. 
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The mode of inhibition of an inhibitor can be determined experimentally by enzyme 
kinetic measurements.  Generally, the kinetic parameters Vmax and Km are determined in the 
presence of varying inhibitor concentrations.  The experimental can be analyzed in the form of 
double reciprocal Lineweaver-Burk plots.  In those plots the deviation of the obtained line from 
the uninhibited line ([I] = 0) indicates the inhibition mode (figure 4.5).  The characteristic 
signatures of the different inhibition modes in the double reciprocal plots are summarized in 







Characteristic signatures of the different inhibition modes in the double reciprocal plots 
 
Inhibition mode Diagnostic signature 
Competitive Intersecting lines that converge at y axis 
Noncompetitive, α > 1 Intersecting lines that converge to the left of y axis and above x 
axis 
Noncompetitive, α = 1 Intersecting lines that converge to the left of the y axis and on the 
x axis 
Noncompetitive, α < 1 Intersecting lines that converge to the left of the y axis and below 
the x axis 






Figure 4.5: Representative double reciprocal plots for different inhibition modes 
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In addition to the determination of binding affinity and binding site, binding specificity 
studies are commonly performed to determine the binding selectivity or uptake in the target cells.  
In pathological conditions like cancers, cells overexpress different receptors/biomarkers which 
are not present at all or present in very low level in normal cells.  This differential receptor 
expression forms the basis of in vitro cell based studies to determine binding selectivity.  CD13 
has been found to be upregulated in different cancers (91, 95).  To evaluate the binding 
selectivity of the peptide ligands, cell surface CD13 binding studies (146) and confocal 
microscopy studies (148, 149) were performed with fluorophore conjugated peptide molecules.  
The in vitro cell surface binding studies provide information about the abilities of the peptide 
ligands to bind to CD13 receptor on the cell surface.  Confocal microscopy images give the 
visual confirmation of binding and cellular uptake. 
4.2 Materials and Methods 
4.2.1 Characterization of CD13 binding affinity and binding site of the peptide 
ligands.  CD13 catalysis inhibition assays were performed to determine the CD13 binding 
affinity and to evaluate the binding sites of the peptide ligands.  His-tagged human CD13 protein 
(Sino Biological, Beijing, China) at 2 nM and 172 µM L-Alanine 7-amido-4-methylcoumarin 
(Ala-MCA) (Santa Cruz Biotechnology, Dallas, TX, USA) were incubated in 96-well 
polystyrene microplates with 100 μL of binding buffer/well (10 mM HEPES and 0.1% w/v BSA 
in PBS, pH 7.2) with gradient concentrations of the peptides at 37 °C.  The release of fluorescent 
product 7-amido-4-methylcoumarin was measured using a BioTek Synergy HT microplate 
reader (BioTek Instruments, Winooski, VT, USA) at λexc of 360 nm and λem of 460 nm.  The 
IC50 is defined as the concentration of the peptide causing 50% inhibition of the CD13 
enzymatic activity.  The steady-state enzyme kinetic assays were performed at room temperature 
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as described above, using incremental concentrations of Ala-MCA (33–526 μM), at fixed 
concentrations of the peptides ranging from 0 to 1304 μM.  Initial rates (V0) were calculated 
from the slopes of the first 5 minutes of the reaction.  The equilibrium dissociation/inhibitory 
constants (Ki) were calculated using the competitive (or noncompetitive, α = 1, depending on the 
observed inhibition mode in the double reciprocal plots) enzyme inhibition model on GraphPad 
Prism (La Jolla, CA, USA). 
4.2.2 Evaluation of CD13 expression levels in selected cell lines.  Western blot studies 
were carried out to detect the CD13 expression levels in HT-1080 and MCF-7 cells.  The cells 
(ATCC, Manassas, VA, USA) were lysed with cell lysis buffer (Cell Signaling, Boston, MA, 
USA) and protein concentrations were determined by the bicinchoninic acid assay (BCA assay).  
Cell proteins (20µg) were then loaded into wells on SDS-PAGE gel (Bio Rad, Hercules, CA, 
USA).  The proteins on gel was then transferred to 0.45 µm nitrocellulose membrane (Bio Rad, 
Hercules, CA, USA), blocked for 1 h with 5% w/v BSA in 0.1% Tween 20-Tris-buffered saline, 
and then incubated overnight at 4°C with primary antibody (Anti-CD13 antibody [EPR4058], 
Abcam, Cambridge, MA, USA).  The membrane was incubated with secondary antibody 
(Donkey anti-Rabbit IgG IRDye 800CW, 1: 10,000) (LI-COR, Lincoln, NE, USA) in the 
blocking buffer for 1 h at room temperature.  The membrane was scanned using a LI-COR 
Odyssey imaging system (Lincoln, NE, USA).  To normalize the protein loading, the blots were 
incubated with β- actin (Cell Signaling, Boston, MA, USA) as a control. 
4.2.3 Evaluation of cell surface CD13 binding of the peptide ligands.  For the cell 
surface CD13 binding assay, CD13 positive HT-1080 cells and CD13 negative MCF-7 cells were 
seeded at 3 - 4 × 104 cells/well, 48 hours before the experiment in 96-well clear-bottom black 
plates.  On the day of experiment, the cells were washed twice with binding buffer before 
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incubating 30 minutes (37 °C, 5% CO2) with each peptide conjugate (60 µM) in the binding 
buffer.  The cells were then fixed with 4% paraformaldehyde in PBS for 10 minutes.  The 
fluorescence intensities were measured using the BioTek Synergy HT microplate reader with 
FITC filter set.  The cells were then counterstained with the nuclear stain Hoechst 33342 and 
analyzed using the same microplate reader with DAPI filter set.  Between each step, the cells 
were washed twice with the binding buffer. 
4.2.4 Evaluation of cell internalization and selectivity of the peptide ligands towards 
CD13.  Cell internalization and selectivity of the designed peptides towards CD13 were 
evaluated in HT-1080 and MCF-7 cell lines using confocal microscopy.  HT-1080 and MCF-7 
cells were seeded on to coverslips placed inside 6-well culture plates at a density of 100,000 
cells/well and incubated for 24 hours.  FITC conjugated peptides were added at a concentration 
of 30 µM at 37 °C, 5% CO2 and incubated for 20 minutes in binding buffer.  Cells were then 
stained with Alexa Fluor 594 (plasma membrane dye) (Invitrogen), fixed with 4% 
paraformaldehyde in PBS, and visualized under a Leica DMIRE2 confocal laser scanning 
microscope (Leica Microsystems GmbH, Germany) at 63X magnification with oil immersion.  
Between each step, the cells were washed twice with the binding buffer. 
4.3 Results and Discussions 
4.3.1 Characterization of CD13 binding affinity and binding site of the peptide 
ligands.  The designed peptides inhibited the CD13 catalyzed hydrolysis of Ala-MCA substrate, 
at significantly lower concentrations than NGR-2C peptide (Figure 4.6 and Table 4.2).  The 
illustrated curve-fittings are based on single inhibitor binding site.  IC50 values observed for the 
designed peptides were 2.7 to 7.4 times lower than that of NGR-2C (Table 4.2). 
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To gain insight into the binding affinity and binding site of the peptide ligands, steady-
state enzyme kinetic assays (Figure 4.7, 4.8, 4.9 and Table 4.2) were performed at room 
temperature.  The Lineweaver-Burk double reciprocal plots for PEP20, PEP24, PEP173, and 
NGR-2C showed series of lines crossing the y-axis (1/V0) at the same point – i.e. Vmax 
unchanged, but with increasing values of Michaelis constant (Km).  These data were consistent 
with competitive inhibition model (PEP20, Ki = 54.0 ± 11.9 µM; PEP24, Ki = 74.3 ± 12.0 µM; 
PEP173, Ki = 38.8 ± 5.21 µM; NGR-2C, Ki = 773 ± 157 µM), suggesting that PEP20, PEP24, 
PEP173, and NGR-2C bind to the catalytic site of CD13.  On the other hand, PEP293 and 
PEP308 were found to lower the Vmax, without affecting Km (Figure 4.9), suggesting that they 
can bind to CD13 in presence of the substrate.  This indicates non-competitive inhibition mode 
for PEP293 (Ki = 137 ± 8.31 µM) and PEP308 (Ki = 234 ± 14.3 µM). 
The three identified peptides [PEP173 (GYPAVYLF), PEP20 (GYPAY) and PEP24 
(GFPAY)] showed 10 – 20 times higher binding affinity (Ki) towards hCD13 as compared to 
NGR-2C peptide.  PEP20, 24 and 173 were found to bind to the catalytic active site of CD13 -the 
intended target site of the designed peptide ligands.  The nonspecific control peptides [PEP293 
(GYPAYVEF) and PEP308 (GFPAVYEF)] were found to bind to sites distant from the intended 

















































































Figure 4.7: Steady state kinetic analysis of CD13 in presence of Ala-MCA substrate, and PEP20 
and PEP24; plots of initial velocity (V0) versus Ala-MCA concentration (upper panels) and 




















































Figure 4.8: Steady state kinetic analysis of CD13 in presence of Ala-MCA substrate, and PEP173 
and NGR-2C; plots of initial velocity (V0) versus Ala-MCA concentration (upper panels) and 









































Figure 4.9: Steady state kinetic analysis of CD13 in presence of Ala-MCA substrate, and PEP293 
and PEP308; plots of initial velocity (V0) versus Ala-MCA concentration (upper panels) and 







CD13 catalysis inhibition assay data 
 
Peptides Sequence IC50 (μM)a, b 
Binding Affinity, 
Ki (μM)c, d 
Inhibition mode 
PEP20 GYPAY 227 ± 6.67 54.0 ± 11.9 Competitive 
PEP24 GFPAY 463 ± 21.8 74.3 ± 12.0 Competitive 
PEP173 GYPAVYLF 170 ± 23.0 38.8 ± 5.21 Competitive 
NGR-2C (+ve 
control) 
CNGRC (C1-C5) 1260 ± 80.0 772.6 ± 157 Competitive 
GARAG (-ve 
control) 
GARAG - - - 
PEP293 GYPAYVEF 213 ± 6.67 137 ± 8.31 Non-competitive 
PEP308 GFPAVYEF 300 ± 40.0 234 ± 14.3 Non-competitive 
a n = 3, Mean ± SE, b All after 30 minutes except NGR-2C after 10 minutes, c Mean ± SE, 
d For PEP20, 24, 173 and NGR-2C, competitive inhibition model was used in Prism 7 to 




4.3.2 Evaluation of CD13 expression levels in selected cell lines.  While HT-1080 cells 
exhibited clear CD13 bands, MCF-7 cells did not show significantly identifiable band of CD13 
in the blots (Figure 4.10).  Based on the band intensity, HT-1080 cells showed ten-fold greater 
CD13 expression than MCF-7 cells.  These data showed the suitability of using HT-1080 and 










4.3.3 Evaluation of cell surface CD13 binding of the peptide ligands.  The ability of 
the peptides to recognize cell surface CD13 receptor was evaluated by measuring the 
fluorescence intensity (cell number normalized) after incubating the FITC-conjugated peptides in 
CD13 positive HT-1080 cells and CD13 negative MCF-7 cells.  In the cell binding assay, all the 
FITC conjugated peptides except the negative control conjugate (GARAG-FITC), showed 
significantly higher cell surface binding to CD13 positive HT-1080 cells as compared to the 




and PEP173) conjugates were found to exhibit slightly higher cell surface binding compared to 
NGR-2C conjugate in HT-1080 cells.  These data suggested that the designed peptides could 











4.3.4 Evaluation of cell internalization and selectivity of the peptide ligands towards 
CD13.  Cell internalization and selectivity of the designed peptides towards CD13 were 
evaluated in HT-1080 and MCF-7 cell lines using confocal microscopy.  Confocal microscopic 
imaging was performed after incubating the cells with the FITC conjugated peptides for 20 

















































significant green fluorescence was observed inside the cells and some fluorescence was detected 
on the cell surface for the designed peptides (PEP20-FITC, PEP24-FITC and PEP173-FITC) and 
NGR-2C-FITC.  The same molecules resulted in only background green fluorescence in MCF-7 
cell images (lower panels of Figures 4.12. 4.13, 4.14, and 4.15).  FITC labeled control peptide 
GARAG showed no binding to both the cell lines (Figure 4.16).  These data demonstrated that 
the designed FITC labeled peptides and the positive control NGR-2C-FITC bound and got 

























Figure 4.12: Confocal images of PEP20-FITC.  Left Alexa Fluor column shows the cell treated 
with membrane dye (red), middle FITC column shows the cells treated with FITC conjugated 

















Figure 4.13: Confocal images of PEP24-FITC.  Left Alexa Fluor column shows the cell treated 
with membrane dye (red), middle FITC column shows the cells treated with FITC conjugated 

















Figure 4.14: Confocal images of PEP173-FITC.  Left Alexa Fluor column shows the cell treated 
with membrane dye (red), middle FITC column shows the cells treated with FITC conjugated 

















Figure 4.15: Confocal images of NGR-2C-FITC.  Left Alexa Fluor column shows the cell treated 
with membrane dye (red), middle FITC column shows the cells treated with FITC conjugated 

















Figure 4.16: Confocal images of GARAG-FITC.  Left Alexa Fluor column shows the cell treated 
with membrane dye (red), middle FITC column shows the cells treated with FITC conjugated 





Chapter 5: Designed Peptide - Drug Conjugate 
5.1 Introduction 
In cancer therapy, the primary objective of targeted drug delivery is to transport drug to 
the cancer sites while minimizing their exposure to normal tissues.  Two key strategies have been 
extensively studied to achieve this goal, both of which rely on modifying the pharmacokinetic 
properties of the drug to some extent.  The first strategy uses a delivery vehicle, like 
nanoparticles, that carries the drug and determines the drug biodistribution via its own 
physicochemical characteristics.  The second one is the prodrug strategy, where covalent 
modification of the drug with a moiety that momentarily disguises the drug's bioactivity and 
confers desirable pharmacokinetic properties.  The prodrug approach have several advantages 
over delivery vehicle approach: (a) significantly lower amount of inert materials that results in 
decreased metabolic burden of the patient (b) minimize premature drug release, (c) relatively 
straightforward and simple preparation/manufacturing (150-152). 
Peptide-drug conjugate (PDC) is an emerging type of prodrug.  It is formed by covalent 
attachment of a specific peptide sequence to a drug through a linker.  The use of peptides would 
enable the incorporation of many functionalities into PDCs.  The amino acid sequences can be 
selected to regulate the physicochemical properties of the conjugate, as well as to impart active 
targeting towards a specific receptor expressed at the target cancer tissue.  PDCs are 
biodegradable and generally show no or minimum undesired immunogenic responses because 
they are composed of amino acids and typically have short peptide sequences.  Different amino 
acid combinations allow simplistic preparation of different PDCs.  A number of tumor targeting 
peptides have been developed till date for different types of cancers.  The peptide sequence can 
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be easily modified to facilitate drug conjugation and, to tune the conjugate molecule ionization 
and hydrophobicity, which in turn impact the bioavailability.  Additionally, owing to their low 
molecular weight, PDCs can be purified by simple HPLC technique (153, 154). 
The main building blocks of a PDC include a cytotoxic drug, a targeting peptide ligand 
and a linker between them (Figure 5.1).  The therapeutic efficacy of the PDC is primarily 
governed by the potency of the cytotoxic drug and the targeting efficiency of the conjugate.  The 
process of synthesizing PDCs is generally fast and simple.  And since an already approved drug 
can be selected as the therapeutic payload, the overall cost of production of PDCs is significantly 










The general mechanism of action of a PDC in cancer therapy is illustrated in Figure 5.2.  
After administration into plasma (step 1), the PDC interacts with the specific antigen on target 
cell surface (step 2).  Then the PDC-antigen complex gets internalized into the cell (step 3).  
Inside the target cell, PDC undergoes lysosomal degradations and release the cytotoxic agent 
(step 4).  Majority of the cytotoxic drugs cause cell death via either DNA intercalation or binding 





























































































The role of linker is very important in the design of PDCs.  There are two classes of 
linkers: (a) cleavable linkers, and (b) non-cleavable linkers.  While cleavable linkers get cleaved 
extracellularly or intracellularly at the target site by different endogenous or exogenous stimuli, 
non-cleavable linkers do not get cleaved.  The non-cleavable linkers undergo degradation in 
lysosome along with the whole conjugate.  The most widely used cleavable linkers are 
hydrazone and disulphide linkers.  Drug-linker moiety is typically linked to peptide or antibody 
using the lysine or thiol groups on the targeting moiety (156, 157). 
Doxorubicin, chlorambucil, camptothecin, and paclitaxel are some of the 
chemotherapeutic drugs that have been used in PDC development (111).  But these drugs are 
relatively low potency cytotoxic drugs.  Currently, very potent cytotoxic agents, like auristatins, 
are used in drug conjugate development (158).  Auristatins leads to cell apoptosis by inhibiting 
the polymerization of tubulin in dividing cells (159). 
Design of a novel peptide-doxorubicin conjugate was reported by Soudy et al.  They 
made two different conjugates having ester and amide bonds between doxorubicin and linker.  
The PDC with ester bond showed 4 times more toxicity than doxorubicin in MDA-MB-435 cells 
and 40 times better selectivity towards breast cancer cell lines when compared to normal cells 
(160).  Polyak et al reported the development of integrin targeted cyclic RGD-PEG-Dox 
conjugate.  The PDC inhibited the cell proliferation at lower IC50 as compared to doxorubicin or 
control conjugate without RGD peptide (161).  An EGFR-binding peptide-doxorubicin conjugate 
was developed and evaluated in-vitro and in-vivo for anti-cancer efficacy.  The study showed 
improved anticancer efficacy and lower systemic toxicity of PDC with EGFR upregulated tumor 
cells (162). 
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In this study, PDCs were prepared by conjugating the drug monomethyl auristatin E 
(MMAE) to the designed CD13 targeting peptides via cleavable linker.  The linker-drug 
construct contains a spacer, maleimidocaproyl (mc); a protease degradable dipeptide, valine-
citrulline (vc); a self-immolative moiety, para-amino benzyloxycarbonyl (PABC); and the 
antimitotic drug, MMAE (Figure 5.3).  This construct is termed as mc-vc-PABC-MMAE.  The 
linker-drug construct can be conjugated to a cysteine residue in the peptide sequence using the 
specific thiol-maleimide coupling reaction (163, 164).  The PDCs were studied to evaluate the 
cytotoxicity and determine the IC50 values.  The studies were performed in CD13 overexpressing 
HT-1080 cells, and CD13 negative MCF-7 cells, and a control normal cell line HEK 293. 
In this study targeting ability of the designed peptide ligands in living host was also 
evaluated by studying the in-vivo anti-tumor efficacy of the synthesized peptide-drug conjugates.  
The use of animal models enables researchers to study disease conditions in ways which would 
be unapproachable in a human patient.  To study cancer efficacy, different animal models are 
available.  These models are typically used to study the reasons of malignant transformation, 
metastasis, and invasion, and to evaluate the response to different anticancer therapies. 
The most extensively used model for studying cancer states is the xenograft model.  In 
xenograft model, tumor cells or tissues are introduced in immunocompromised mice, either 
under the skin or directly into the organ where the tumor originates.  The immunocompromised 
mice do not reject the transplanted exogenous cells.  Xenograft can be developed in athymic 
nude mice, severely compromised immunodeficient (SCID) mice, or other immunocompromised 
mice breeds (165).  The tumor develops in 1 week to 4 months depending on the number of cells 
transplanted, or the size of the transplanted tumor tissue.  The response to therapeutics can then 























































Fmoc-L-Cys(Trt)-2-chlorotrityl resin, Fmoc-amino acids, Boc-amino acids, Fmoc-
aminohexanoic acid, N, N′-diisopropylcarbodiimide (DIC), diisopropylethylamine (DIPEA), 
triisopropylsilane (TIS), N-hydroxybenzotriazole (HOBT) were purchased from Chem-Impex 
International Ltd (Wood Dale, IL, USA).  Maleimidocaproyl-valine-citrulline-p-
aminobenzoyloxycarbonyl-monomethyl auristatin E (mc-vc-PABC-MMAE) and monomethyl 
auristatin E (MMAE) were obtained from MuseChem (Fairfield, NJ, USA) and MedKoo 
Biosciences (Morrisville, NC, USA), respectively.  Sulforhodamine B (SRB) assay kit was 
purchased from Abcam (Cambridge, UK).  All chemicals and solvents were used without further 
purification. 
HT-1080, MCF-7, and HEK 293 cells were purchased from ATCC (Manassas, VA, 
USA).  Cells were cultured in dulbecco’s modified eagle medium (DMEM)  (high glucose, with 
L-glutamine, and sodium pyruvate) (Thermo Fisher Scientific, Waltham, MA, USA) with 10% 
fetal bovine serum (Gemini Bio-Products, West Sacramento, CA, USA) and 1% penicillin-
streptomycin (Gemini Bio-Products, West Sacramento, CA, USA).  TrypLE Express was 
obtained from Thermo Fisher Scientific (Waltham, MA, USA). 
Four to six weeks old female athymic nude mice (nu/nu) were purchased from Simonsen 
Laboratories (Santa Clara, CA, USA).  The medical supplies like syringes, and alcohol swabs 
were purchased from Beckton Dickinson (Franklin Lakes, NJ, USA).  Isoflurane was obtained 




5.3.1 Synthesis of the peptide-drug conjugates (PDCs).  The peptides (PEP20-Ahx-
Cys, GYPAY-Ahx-C; and PEP173-Ahx-Cys, GYPAVYLF-Ahx-C) were synthesized by 
standard solid phase synthesis method (0.2 to 0.4 mmol scale).  The synthesis was started with 
Fmoc-L-Cys(Trt)-2-chlorotrityl resin to place a cysteine residue at the C-terminal so that the 
drug-linker construct can be conjugated at the C-terminal side of the peptide (Figure 5.4).  A 
spacer (e.g. 6-aminohexanoic acid/ Ahx) was added between the designed peptide sequence and 
the C-terminal cysteine residue using same DIC/HOBt coupling method.  Coupling of 
subsequent amino acids was performed with 3 to 5 fold excess of 1-hydroxy-benzotriazole 
(HOBt) and diisopropyl-carbodiimide (DIC).  Each coupling was done for 3 hours, followed by 
Kaiser test to confirm the completeness of reaction.  Fmoc group was removed in each step by 
treating the resins was solution of 20% piperidine in DMF.  Kaiser tests were also performed 
after each deprotection step.  Boc protected amino acids were used only for the last N-terminal 
amino acids to eliminate the necessity of last Fmoc deprotection step.  Cleavage of the peptides 
were done by treating the resins with trifluoroacetic acid – water – triisopropylsilane (95: 2.5: 
2.5) cocktail for 3 hours.  The obtained TFA-peptide solution was cooled and evaporated under 
nitrogen flow until it became thick viscous oily liquid.  Ice cold ether was added to the oily 
liquid to precipitate the peptide.  The peptides are then freeze dried and stored in −20° C freeze 
until further use.  The peptides were used to synthesize the PDCs without further purification. 
The PDCs were prepared using thiol-maleimide coupling reaction.  To synthesize each 
PDC (Figure 5.4), 5mg of the peptide was dissolved in 2.5 ml of PBS-ACN (70:30) mixture, and 
equimolar amount of mc-vc-PABC-MMAE was dissolved separately in 2.5 ml PBS-ACN 
(70:30) mixture.  The peptide solution and the drug-linker solution were mixed thoroughly by 
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vortexing.  The pH of the reaction mixture was adjusted to 6.5 – 7 using HCl (aq).  The reaction 





















































5.3.2 Characterization of the synthesized molecules.  Synthesized molecules were 
characterized by Electron Spray Ionization Mass Spectrometry (ESI-MS, AB Sciex PI 3000).  
Samples were made in acetonitrile and water mixture (50:50). 
The purity of the synthesized molecules was determined using high pressure liquid 
chromatography (HPLC) (Agilent 1100).  The column used was Agilent Zorbax C18, 5 μm, 
4.6×150 mm, and the wavelengths used for detection were 210, 254 and 280 nm.  The samples 
were eluted with a mobile phase consisting of water (A) and acetonitrile (B) using a linear 
gradient from 10 to 90% B over 30 to 35 minutes, at 1.0 mL/min flow rate.  The purified 
compounds were freeze dried and stored at -80° C. 
5.3.3 In vitro cytotoxicity of peptide-drug conjugates.  The cytotoxicity study of 
MMAE and peptide-drug conjugates was performed using CD13 overexpressing HT-1080 cells, 
CD13 non-expressing MCF-7 cells, and a control normal cell line HEK293.  The cells were 
grown in 75 cm2 flasks in DMEM with 10% FBS and 1% penicillin-streptomycin at 37° C and 
5% CO2.  The cells were detached using TrypLE Express and the cell density was counted using 
Scepter Automated Handheld Cell Counter (MilliporeSigma, Burlington, MA, USA).  The cells 
were seeded into clear 96 well plates at 5000 cells/well (0.2 mL cell suspension/well) and 
incubated overnight to allow them to attach to the wells.  Then the cells were incubated with 
drug MMAE and peptide-drug conjugates at various concentrations ranging from 0.0000302 to 
30200 nM for 72 h at 37° C and 5% CO2 (in complete growth media).  The Sulforhodamine B 
(SRB) Cell cytotoxicity assays were performed following the company recommended protocol 
(SRB assay kit, Abcam, ab235935).  The SRB absorbance was measured at 490 nm wavelength 
by using a microplate reader (BioTek Instruments, Inc., VT, USA). 
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Percent cytotoxicity was calculated by the following formula: 
𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 %  




O.D. (DMSO) = absorbance of the DMSO control after background correction. 
O.D. (Sample) = absorbance of the sample after background correction. 
 
The IC50 values were determined using Graph Pad Prism 7 software (GraphPad Software 
Inc., CA, USA) with nonlinear regression dose-response - inhibition curve fit (variable slope four 
parameter). 
5.3.4 In vivo anti-tumor efficacy of peptide-drug conjugates.  The in vivo study was 
performed as per the animal protocol (No. 17R02) reviewed and approved by the Institutional 
Animal Care and Use Committee, University of the Pacific. 
5.3.4.1 Determining maximum tolerated dose (MTD) of the drug MMAE.  The MTD of 
the drug MMAE was determined in four to six weeks old female athymic nude (homozygous, 
nu/nu) mice.  Five healthy mice were given a single dose of 0.375 mg/kg, 0.5 mg/kg, 0.7 mg/kg, 
1 mg/kg, and 1.5 mg/kg of MMAE, respectively via tail vein injection using 29 gauge needles.  
Following administration, the mice were observed daily for their general health and the body 
weight was measured every three days. 
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5.3.4.2 Xenograft model.  CD13 overexpressing HT-1080 cells were cultured as 
described previously in Section 5.3.3.  On the day of tumor transplantation, cells were detached 
using TrypLE Express and re-suspended in DMEM.  The cell density was counted using Scepter 
Automated Handheld Cell Counter.  The cells were centrifuged at 125xG for 5 minutes and the 
supernatant was discarded.  The cell pellet was washed once with sterile PBS and re-suspended 
in 50:50 PBS – Matrigel (High Concentration) (Corning Life Sciences, Tewksbury, MA, USA) 
so that 0.1 mL of the suspension contains approximately 1,000,000 cells.  The cell suspension 
was maintained on ice until injection. 
Four to six weeks old female athymic nude mice (homozygous, nu/nu) were used for 
tumor xenograft model development.  All mice were anaesthetized using isoflurane.  0.1 mL of 
cell suspension was injected subcutaneously on the right flank of each mouse using a 27 gauge 
needle.  Following inoculation, the mice were observed daily for their general health and tumor 
appearance. 
5.3.4.3 Anti-tumor efficacy study.  Tumors in mice were grown to reach an average of 
approximately 100 mm3.  The tumor bearing mice were then divided in to four groups each 
having four mice.  The groups were PBS group, MMAE group, PEP20-MMAE group, and 
PEP173-MMAE group.  Treatment was started 9 or 12 days after cancer cell transplantation and 
was administered intravenously via tail vein using 29 gauge needles every 4 days for a total of 4 
doses (q4d X 4).  The dose was 975 nmol/kg for each compound which is equivalent to 0.7 
mg/kg MMAE.  The greatest longitudinal diameter (L) and the greatest transverse diameter (W) 
of the tumor were measured using Vernier caliper every four days from the day of first dosing.  
Tumor volume was determined using the formula (L X W2)/2.  The body weights were also 
measured every four days. 
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5.4 Results and Discussions 
5.4.1 Synthesis and characterization of peptide-drug conjugates (PDCs).  Designed 
peptides PEP20 and PEP173 were chosen as the targeting peptide moieties for the synthesis of 
PDCs.  The anticipated binding mode of the designed peptides indicates that the N-terminal side 
binds deep inside the peptide binding channel of CD13 (Figures 2.6, 2.7, and 2.8).  Moreover, it 
has been reported that, any modification at the N-terminal of the conventional CD13 targeting 
peptide ligand CNGRC (C1-C5) hampers its binding ability (166).  Therefore, a cysteine 
conjugation site was incorporated at the C-terminal side of the peptides (PEP20 and PEP173) 
under study.  A spacer (6-aminohexanoic acid) was added in between the designed peptide 
sequence and the cysteine conjugation site to have spatial separation between the targeting 
peptide moiety and the linker-drug moiety. 
The peptides (PEP20-Ahx-Cys and PEP173-Ahx-Cys) were conjugated to monomethyl 
auristatin E (MMAE), a highly potent but non-selective tubulin polymerization inhibitor, through 
a maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (mc-vc-PABC) linker.  The 
maleimidocaproyl (mc) part of the linker-drug motif (mc-vc-PABC-MMAE) utilizes maleimide 
chemistry for cysteine linkage, which takes advantage of exceptional reactivity of maleimide 
towards sulfhydryl groups to form stable thioester bond.  Valine-citrulline (vc) dipeptide is an 
intracellular protease, cathepsin B, sensitive linker.  This protease sensitive approach uses the 
main proteases found in the tumor cell lysosome for identification and cleavage of a specific 
peptide sequence.  The para-amino benzyloxycarbonyl (PABC) moiety in the linker-drug motif 
is a self-immolative spacer (164, 167). 
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All the products were characterized by ESI-MS as shown in table 5.1.  The mass spectra 
of PEP20-Ahx-Cys and PEP173-Ahx-Cys were observed as singly charged species and are 
displayed in figures 5.5, and 5.7.  Peptide drug conjugates PEP20-MMAE (PEP20-Ahx-Cys-mc-
vc-PABC-MMAE), and PEP173-MMAE (PEP173-Ahx-Cys-mc-vc-PABC-MMAE) were 
observed as double and triple charged species and are displayed in Figures 5.9, and 5.11, 
respectively.  The HPLC analysis of the compounds used after purification were greater than 

















PEP20-Ahx-Cys 808.9 [M+Na]+ 808.8 80.5 
PEP173-Ahx-Cys 1144.3 [M-H]- 1144.2 80.9 
PEP20-MMAE (PEP20-Ahx-Cys-
mc-vc-PABC-MMAE) 
1062.5 [M+H+Na]+2 1062.9 98.1 
PEP173-MMAE (PEP173-Ahx-Cys-
mc-vc-PABC-MMAE) 


































































































































































































































































































5.4.2 In vitro cytotoxicity studies.  Cytotoxicity studies were carried out to evaluate the 
potency of the free drug, and peptide drug conjugates.  Percentage cytotoxicity was calculated 
using sulphorhodamine B assay. 
MMAE showed very high potency (low IC50 values) across all three cell lines (Table 
5.2).  For all three cells lines, PDCs (PEP20-MMAE and PEP173-MMAE) showed significantly 
lower cytotoxicity than MMAE in the cell culture medium (Figures 5.13, 5.14 and 5.15, and 
Table 5.2). 
PEP20-MMAE showed 5.2 and 4.3 times lower cytotoxicity in CD13 negative MCF-7 
and control normal HEK-293 cells, respectively, when compared to that in CD13 positive HT-
1080 cells (Figures 5.13, 5.14 and 5.15, and Table 5.2).  PEP173-MMAE was found to have 
approximately 2.4 times less cytotoxicity both in MCF-7 cells and HEK-293 cells as compared 
to HT-1080 cells (Figures 5.13, 5.14 and 5.15, and Table 5.2).  The PDCs seemed to have 
specificity trend towards CD13 positive HT-1080 cells as evidence by the lower IC50 in the HT-
1080 cells.  However, as compared to the HT-1080 cells, the drug MMAE was also found to be 
4.5 and 8.9 times less cytotoxic (in terms of IC50) in MCF-7 cells and HEK-293 cells, 
respectively (Figures 5.13, 5.14 and 5.15, and Table 5.2).  This indicates that the conjugation of 
peptide-linker construct to the drug decreased the potency of MMAE rather than improving 
selectivity. 
There could be several reasons behind the lower cytotoxicity of the PDCs as compared to 
MMAE.  One possibility could be higher protein binding of the PDCs or interference by fetal 
bovine serum present in the cell culture medium in which the cells were incubated with 
PDCs/drug.  Liraglutide, a human glucagon-like peptide-1, was reported to exhibit 
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approximately 99% serum protein binding in vitro (168).  Hsiao IL and Huang YJ observed 
significantly lower in vitro cytotoxicity of ZnO particles in serum containing medium as 
compared to the serum free medium (169).  A dual targeting NGR-peptide−drug conjugate also 
showed significantly lower in vitro cytotoxicity than the drug itself in serum containing medium 
(170).  The designed peptides might also lose their targeting ability after conjugating to the 
linker-drug construct owing to the large size of the construct.  The size of the drug-linker 
construct (mc-vc-PABC-MMAE) is bigger than the peptides.  While, the molar weight of 
PEP20-Ahx-Cys and PEP173-Ahx-Cys are 785.91 and 1145.3 g/mol, respectively, the molar 
weight of the linker-drug construct is 1316.6 g/mol.  It has been reported that conjugation 
induced perturbations in the peptide structural microenvironment can lead to diminished binding 
affinity to the target receptor (155).  Peng ZH and Kopeček J have shown that the cell 
penetrating cyclic peptide iRGD (CRGDKGPDC) lose its targeting ability after conjugating to 










MMAE PEP20-MMAE PEP173-MMAE 
HT-1080 (CD13 +ve) 0.09358 ± 0.01086 92.54 ± 13.38 72.68 ± 9.910 
MCF-7 (CD13 -ve) 0.4250 ± 0.08300 477.9 ± 89.67 175.0 ± 21.30 

























































































5.4.3 In vivo anti-tumor efficacy study.  To select the therapeutic doses of the 
compounds in the in vivo study a maximum tolerated dose (MTD) was determined.  MMAE was 
injected into healthy athymic nude mice at doses ranging from 0.375 mg/kg to 1.5 mg/kg (n=1 
for all doses, except for 0.70 mg/kg n=2).  General health and body weight of the mice were 
monitored for 15 days after injection (Figure 5.16).  Doses up to 0.70 mg/kg of MMAE were 
well tolerated with no apparent sign of toxicity.  At 1.0 mg/kg dose, the mouse experienced 
around 20% weight loss within 6 days of injection and then started regaining weight.  The mouse 
returned to initial body weight by day 15.  The mouse receiving 1.5 mg/kg of MMAE lost more 
than 30% of the body weight by day 6 at which point the mouse was euthanized.  Thus, the MTD 
of MMAE in female athymic nude mice (4-6 weeks old) was determined to be between 1.0 
mg/kg and 1.5 mg/kg.  The maximum tolerated dose (MTD) of dolastatin 10 in mice was 
reported to be approximately 0.45 mg/kg (172).  Dolastatin 10 is a cytotoxic agent whose 
structure is similar to MMAE (173).  Francisco et al reported the MTD of MMAE in SCID mice 
to be between 0.50 mg/kg and 1.0 mg/kg (163). 
For this anti-tumor efficacy study, 975 nmol/kg, which is equivalent to 0.70 mg/kg of 
MMAE, was selected as the treatment dose (MMAE, PEP20-MMAE, and PEP173-MMAE).  
Treatment was started when the average tumor volume reached approximately 100 mm3 (9 or 12 
days after tumor cell injection).  Mice were administered with the drug or PBS treatment every 4 
days for a total of 4 doses (q4d x 4).  In the mice treated with only PBS, the tumor grew rapidly 
and reached approximately 450 mm3 by day 28 after tumor implantation (Figure 5.17).  MMAE, 
PEP20-MMAE, and PEP173-MMAE all showed almost complete tumor regression during the 
study (Figure 5.17).  PEP20-MMAE and PEP173-MMAE showed slightly higher tumor 
regression than MMAE, but the difference was not significant.  As described before in section 
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5.4.2, the insignificant difference in antitumor activity between the drug MMAE and PDCs may 
also be due to higher plasma protein binding of the PDCs or the diminished targeting ability of 
the peptides after conjugating with the larger linker-drug construct.  Additionally the degradation 
of PDCs in circulation by different enzymes may have contributed to this observation.  
Enzymatic degradation in systemic circulation has long been one of the major challenges for the 
peptide based drugs (174). 
Although, the PDCs have comparable anti-cancer efficacy in mouse as compared to the 
drug MMAE, the groups treated with PEP20-MMAE and PEP173-MMAE showed a body 
weight increase of 4% and 8%, respectively, even after fourth dose (25 and 28 days after tumor 
implantation) (Figure 5.18).  On the other hand, the drug MMAE treated group lost body weight 
after dosing started and had a maximum weight loss of 10% after 28 days of tumor implantation 
(Figure 5.18).  Weight loss is one of major adverse effects of anticancer agents due to high and 
non-selective cytotoxic potency (175).  The PDCs (PEP20-MMAE and PEP173-MMAE) have 

































































































Chapter 6: Summary and Conclusions 
Structure based design plays a crucial role in developing novel molecules/drugs.  This 
approach to ligand design utilizes three-dimensional information of a target protein to improve 
recognition and discrimination by identifying favorable residue interactions.  The first 
therapeutic peptide designed from crystal structure analysis was enfuvirtide, which received the 
US-FDA approval as an anti-HIV peptide in 2003 (76).  Foy et al (176) designed vaccines 
against EGFR by selecting different regions from the crystal structure of the protein.  A VEGFR-
3 targeted peptide ligand was developed by analyzing the crystal structure of the extracellular 
domain of VEGFR-3 (177).  Recently, Joshi et al (178) reported the design of a peptide that 
inhibits the enzymatic activity of CD13.  The peptide was developed by a substrate-based 
approach where crystal structures of CD13 with different amino acids were solved to determine 
the structural basis of the substrate specificity.  The structural insights of the protein-ligand 
interaction obtained from the crystal structures have culminated in several computational peptide 
design approaches.  However, it is quite evident that most of these approaches are based on 
either sequence motifs or protein complexes (59).  A rational design method based on the 
predicted interaction between target and ligand molecule will significantly speed up this 
development process. 
In this study, a Knob-Socket analysis of protein packing structure was used to rationally 
design peptide ligands with specificity for the CD13 active site.  The method begins with 
mapping the target protein binding site to characterize the amino acid packing arrangements in 
terms of three residue sockets on the target receptor that pack ligand knob residues- in this study 
the prototype receptor used was CD13.  From the sockets identified as important for ligand 
binding on the surface of CD13, a set of knobs with high propensity interactions were selected.  
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This set of amino acids enabled peptide sequences to be designed rationally by predicting the 
packing of the peptide ligand at the binding site.  The peptides were screened in silico by a 
docking programs to identify the best peptide candidates.  
From the design approach, 412 potential peptide sequences were reduced to just 3 
candidates.  The three identified peptides showed selective binding to human CD13 receptor in 
vitro.  In the enzymatic assay, the designed peptides exhibited higher CD13 catalysis inhibition 
than the CNGRC (C1-C5) peptide (NGR-2C).  NGR-2C showed significantly reduced inhibition 
of CD13 enzymatic activity within 30 minutes (Figure 4.6), suggestive of its’ unstable 
physicochemical characteristics at the assay condition.  This phenomenon is not unexpected 
since the NGR-2C peptide has been reported to lose CD13 binding ability rapidly through 
deamidation of the Asn residue (179).  The success of therapeutic peptides or peptide ligands 
depends on the delivery of their active form at the target site.  The physicochemical stability of 
the peptides is largely influenced by the amino acid composition and sequences of the peptides 
(180-182).  In our rational design method peptides having potentially unstable amino acids or 
sequences can be excluded at the very beginning of the development works during peptide 
screening phase.  
The three identified peptides [PEP173 (GYPAVYLF), PEP20 (GYPAY) and PEP24 
(GFPAY)] showed 10 – 20 times higher binding affinity (Ki) towards hCD13 as compared to 
NGR-2C peptide (773 µM) (Table 4.2).  In other reported studies, IC50 of the NGR-2C peptide 
was 300-515 µM, and the Ki was 134µM (145, 146).  Unlike the fluorescence-based method 
used in the present study, those reported experiments used either L-leucine-p-nitroanilide or L-
alanine-p-nitroanilide as the catalysis substrate, and the formation of p-nitroaniline product was 
measured by the absorbance at 405 nm.  The compositions of the assay buffer were also different 
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in these studies.  But generally, fluorescence-based detection techniques are more sensitive than 
the absorbance-based methods (183).  
Ranking of the three peptides (PEP173, PEP20 and PEP24, respectively) according to 
their experimental binding affinities, Ki, (38.8 µM, 54.0 µM, 74.3 µM, respectively) was in 
agreement with the ranking predicted by the MOE docking scores (-16.2385 kcal/mol, -13.9095 
kcal/mol, -11.9234 kcal/mol, respectively).  Additionally, as predicted by the AutoDock Vina 
(Figure 2.8 and Table 2.4), PEP20, PEP24 and PEP173 were found to bind to the catalytic active 
site of CD13 in the experimental steady-state enzyme kinetic assay (Figures 4.7 and 4.8, and 
Table 4.2).  AutoDock Vina also accurately predicted the distant binding sites of the nonspecific 
control peptides [PEP293 (GYPAYVEF) and PEP308 (GFPAVYEF)] as experimentally 
confirmed by their observed noncompetitive inhibition mode in enzymatic assay (Figure 4.9 and 
Table 4.2).  These findings suggest that the combination of multiple docking platforms in our 
design method could accurately predict the binding characteristics (affinity ranking and binding 
site) of the designed peptide ligands.  Data from the cell binding and confocal microscopy assays 
(Figures 4.11 – 4.16) further demonstrated that the designed peptides could recognize and 
selectively bind to the CD13 on the cell membrane. 
The NGR-motif containing peptide ligand (i.e. CNGRC) for CD13 was first identified by 
an in vivo phage display selection study in a mouse model (98, 103).  Thus, the prototype target, 
CD13 receptor, allowed us to compare the performance of our rational peptide ligand design 
method with the structure free design technique in terms of in vitro binding affinity and 
selectivity of the identified peptide ligands.  A typical in vivo phage display screening starts with 
generating a large library of phage particles expressing a wide array of peptides on their surface.  
The size of the library can reach up to 100,000,000 – 1,000,000,000 different variants (184).  The 
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phage display library proceeds through several enrichment screening cycles, which involves 
binding, phage amplification, and plaque isolation.  The final step is sequencing.  Additional 
validation of the interaction may involve immunohistochemistry, real time PCR, bio-distribution 
and homing inhibition studies (185).  On the other hand, our design method rationally identified 
CD13 selective peptide ligands having better in vitro binding affinity with much less screening 
and experimental complexity. 
The in vitro cytotoxicity studies of the designed peptide-drug conjugates (PEP20-MMAE 
and PEP173-MMAE) indicated that the conjugation of peptide-linker construct to the drug might 
have just decreased the potency of MMAE rather than providing selectivity.  This was further 
observed in the in vivo anti-tumor efficacy studies where the peptide-drug conjugates (PDCs) 
and the drug MMAE showed insignificant difference in antitumor activity.  One possible reason 
could be higher protein binding of the PDCs or interference by fetal bovine serum present in the 
cell culture medium in which the cells were incubated with PDCs or drug for the cytotoxicity 
assays.  Secondly, the peptides might have lost their targeting ability after conjugating to the 
linker-drug construct owing to the large size of the construct.  The size of the drug-linker 
construct (mc-vc-PABC-MMAE) is bigger than both the peptides.  Therefore, there is a 
possibility that the bigger and hydrophobic linker-drug moiety might have altered the binding 
properties of the CD13 targeted peptides.  One additional reason could be the degradation of 
PDCs in circulation by different enzymes.  van Hensbergen et al previously reported the CD13 
targeted peptide-drug conjugate, Doxorubicin-CNGRC (C1-C5), to show no added advantage as 
compared to the drug, doxorubicin, in terms of in vitro cytotoxicity and in vivo antitumor effects 
(186).  In the in vivo study, weight loss was higher in the doxorubicin treated group as compared 
to PDC group (186). 
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In conclusion, in the present study a rational peptide ligand design method based on the 
Knob-Socket model of protein packing was developed and successfully employed to identify 3 
novel peptide ligands for the model receptor, CD13.  The identified peptides showed good 
selectivity and higher binding affinity towards the hCD13 receptor in vitro as compared to the 
known peptide ligand CNGRC (C1-C5).  Our study demonstrated the feasibility of the rational 
method to design novel peptide ligands.  Most importantly, the rational method excluded the 
need of long experimental screening of a vast library of peptide sequences, and thus significantly 
reduces the time and resources traditionally employed to identify such molecules.   
The limited effectiveness of peptide drug conjugates in the in vivo mice tumor model 
suggested the need to improve the designed peptide-MMAE drug conjugates.  Future research 
should focus on achieving the optimal chemical configuration of the conjugates for in vivo 
targeting and receptor mediated cellular uptake.  The current computational simulation studies is 
limited to project binding of the peptides to the target protein.  In future, peptide design with 
higher number of amino acids in the targeting moiety, and smaller linker-drug construct  
(especially small molecules) may be used to conserve the target binding ability of the PDCs.  
Serum stability and plasma protein binding of the PDCs should be carried out to explain a more 
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